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ABSTRACT 
Hypoxia in tumors causes adverse effects to therapy and negatively impacts on 
patient prognosis. Identification and quantification of hypoxia is considered to have a 
strong impact on treatments in tumor therapy. Fluorescent-based detection to mark 
hypoxia may be vital to be used along with available methods such as radiochemical and 
immunohistochemical staining.  
In this work, the non-fluorescent 6-nitroquinoline (42) was used to investigate the 
production of a fluorescent 6-aminoquinoline (43) and other metabolites under bio-
reducing hypoxic conditions. In the presence of the enzymatic reducing system 
NADPH:cytochrome P450 reductase/NADPH, 6-nitroquinoline (42) produced the 
fluorescent helicene (44), along with the non-florescent azo (45). An authentic sample of 
(44) was chemically synthesized and characterized and used to confirm the production of 
this molecule in the enzymatic process. Interestingly, the expected fluorophore (43) is not 
produced by NADPH:cytochrome P450 reductase/NADPH.  
In another study, the enzymatic reducing system xanthine/xanthine oxidase was 
used to reduce (42) under hypoxia to obtain (43). In these experiments (43) was produced 
and the yield is increased with xanthine concentration. Metabolic identification revealed 
that intermediates of typical nitro reduction pathway are present along with 6-
nitroquinolone (51).which is formed by xanthine oxidase mediated oxidation of (42). The 
absence of (44) as a metabolite with xanthine/xanthine oxidase system highlights the 
complexity of bio-reduction of nitroaromatics under hypoxia.  
xxvii 
 
In our laboratory, bio-activation of di-N-oxides such as tirapazamine (TPZ, 42) 
has been studied. TPZ undergoes one-electron bio-reduction to produce oxidizing radical, 
which causes DNA damage under hypoxia. In our laboratory, the mechanism by which 
TPZ mediated DNA damage has been investigated using TPZ and its analogs.  
Our evidence suggests that upon undergoing bio-reduction, TPZ produces 
hydroxyl radical as the DNA damaging radical species. Others have suggested another 
mechanism, which proposes the formation benzotriazine radical (38) upon dehydration 
process over the bioreduction step. In the current work, TPZ analog 1,2,4-benzotraizine-
1,4-dioxide (55) and deuterated (60) were used to test the dehydration mechanism. 
Isotopic content analysis of metabolites, derived from bio-reducing metabolism of (55) 
and its deuterated analog (60), using HRMS show evidence against the dehydration 
mechanism.  
1 
 
 
Chapter 1  
Nitroaromatics and N-oxide compounds as radiosensitizers, oxygen 
sensors and cytotoxic agents in tumor therapy 
1.1 Hypoxia.   
 Low oxygen levels (hypoxia) is considered as an important physiological factor in 
tumor biology.1 The oxygen concentration, found in a normal tissue falls within a range 
of 20 µM to 90 µM.2 It is well established that solid tumors contain cell populations 
having low oxygen concentrations.3 Hypoxia is the end physiological result, caused by 
the presence of irregular vasculature in tumors.4 The inconsistent blood flow in tumors 
may produce acute or chronic hypoxia.1 Hypoxic conditions can diminish effects of 
ionizing radiation mediated tumor therapy.5 Ionizing radiation is a key method in tumor 
therapy and hypoxia has drawn attention as a challenge which should be addressed to 
achieve clinical success.6 
1.2 Ionizing radiation therapy  
In the presence of ionizing radiation water molecules break down to form highly 
reactive, oxidizing hydroxyl radicals (Scheme 1.1).7  
 
Scheme 1.1. Gamma radiolysis generates radical species 
The hydroxyl radical is able to abstract hydrogen from organic substrates such as DNA, 
which can cause cell death (Scheme 1.2).8 
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Scheme 1.2. Hydroxyl radical abstract hydrogen from DNA 
The oxidative abstraction of hydrogen atoms from DNA produces DNA radicals.9 
DNA radicals can be created on the DNA bases or on sugar phosphate backbone. DNA 
radicals, formed on thymidine or guanine DNA bases would develop into strand breaks.10 
The hydrogen atom abstraction, which occurs on the sugar phosphate backbone produces 
carbon centered radicals on C1’, C2’, C3’, C4’and C5’corbons and oxygen is required to 
make the radical damage permanent and induce strand breaks.9 The radical fixation, 
which is mediated by oxygen on DNA backbone carbon radicals, produces characteristic 
DNA lesions.11 The damage, on C4’ and C5’carbons, produces 3’-phosphoglycolate and 
strand breaks (Scheme 1.3).12  
 
 
 
 
 
 
Scheme 1.3. DNA radical on C4’ is fixed by oxygen 
 Formation of a ribonolactone occurs when oxygen fixes a C1’ DNA radical.13 
Under basic conditions 1, ribonolactone undergo elimination to yield strand breaks. 
(Scheme 1.4).8  
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Scheme 1.4. Formation of ribonolactone 
Once the DNA damage, either on backbone or DNA base, is made permanent by 
producing stand breaks, a cascade of cellular events triggers cell death.14  
Under hypoxic conditions, the low oxygen levels diminish DNA radical fixation.3 
Hence DNA radical-mediated cell death might not occur in solid tumors.15 It is noted that 
the DNA radicals created by ionizing radiation would be trapped by cellular thiols such 
as glutathione.7, 16 The chemical repair of DNA damage by thiols under low oxygen 
levels may cause the tumor cell resistance to radiation therapy.13 The cellular glutathione 
levels are present in millimolar levels under physiological conditions (Scheme 1.5).7 
 
 
 
 
 
Scheme 1.5. Thiols can repair DNA radical damage 
 Accordingly, the fate of DNA radicals in tumors depends on the oxygen 
concentration of the cell.8 The lack of oxygen causes tumor cell to resist radiation 
therapy.3 Thus there was a need for alternative agents that can fix DNA radicals under 
low oxygen concentrations to potentiate radiation therapy.  
 
OO
O
O2Base OO
O
Base
O O
OO
O
O
+ BH
1
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1.3 Radiosensitizing oxygen mimetic agents 
In an effort to reduce tumor cell resistance to radiation therapy, investigations 
have been carried out to find agents that can mimic the behavior of oxygen in 
radiotherapy.17 As a part of the search nitro aromatic and N-oxide drugs have been tested 
as radiosensitizing agents to accompany radiotherapy in treatments.17b  
 Potential agents such as TEMPO and misonidazole, 2 were tested in cytotoxicity 
assays with radiation.18 Nitroaromatics became the leading candidates in the search for 
radiation sensitizing agent.17a The sensitizing capacity of nitroaromatics can be radical 
fixation which can occur through oxygen mimetic ability of nitro group. Or the ability of 
nitro group to undergo reduction to form amine can be contribute for the radiation 
sensitivity.17a The higher electron affinity of nitroaromatic compounds can facilitate 
oxidation of DNA from which the charge distribution has been altered by radiolysis.19 
This can produce DNA radical cations and oxygen sensitive nitroradicals which oxidize 
back to parent nitro group in the presence of oxygen (Scheme 1.6).10 
 
 
 
  
 
 
Scheme 1.6. Radiolysis induced nitro-reduction and DNA radical formation 
There is evidence for donation of an oxygen atom from a nitro group to a DNA 
radical.20 Goldberg and researchers used an 18O-labeled nitro group containing 
5 
 
misonidazole 2 and DNA radical precursors in his 18O-incorporation experiments. When 
misonidazole interacts with C5’ DNA radical, nitroxide intermediate forms, followed by 
fragmentation caused strand breaks (Scheme 1.7).21  
  
 
 
 
Scheme 1.7. Oxygen of nitro group is donated to DNA 
Further studies on misonidazole-mediated radionsensitization revealed that 2 
causes toxicity without ionizing radiation.22 The higher electron affinity of nitroaromatic 
compounds makes them substrate for cellular reductases.23 It was suggested that cellular 
reducing systems such as NADPH cytochrome P450 reductase may reduce nitro group to 
hydroxylamine and to amine groups via six consecutive e- reduction steps under hypoxic 
conditions (Scheme 1.8).24  
 
 
Scheme 1.8. Enzyme mediated Nitro reduction undergo in hypoxia 
 The hydroxylamine intermediate may cause cytotoxicity by forming reactive 
intermediates.25 The reduction of 2-nitro-5-alkyl-nitroimidazole 3 would produce the 
hydroxylamine and then converts to the glyoxal-dialdehyde 4 form which may alkylate 
nucleophilic sites on DNA (Scheme 1.9).26 
 
 
6 
 
 
 
 
Scheme 1.9. Hydroxylamine produces glyoxal-dialdehyde alkylator 4 
 The clinical test, carried out using 2 produced neurotoxicity among patients. The 
observed toxicity may have arisen due to the formation of hydroxylamine intermediate.  
1.3.1 Nitroaromatic reduction in hypoxic cells 
 Studies on reduction of nitroaromatic-radiosensitizing drugs established nitro 
reduction mechanism which may occur in cells.17a, 27 The stepwise electron addition 
would produce the hydroxylamine intermediate. Further reduction produces the amino 
product.28 The nitro group reduction is mediated by cellular enzymes such as NADPH 
cytochrome P450 reductase, xanthine oxidase, nitroreductases and DT diaphorase.17a, 24 
These enzymes can be overexpressed or already abundant in tumor environment.27, 29 The 
hypoxic conditions in tumors would permit sequential e- reduction to occur and produce 
reduced metabolites such as hydroxylamine and amine.30 The enzyme-mediated 
functional group transition from nitro to hydroxylamine has been considered as an 
electronic switch.27 The electron poor nitro group is converted to an electron rich 
hydroxylamine, and further reduction produces the amine moiety.31 For some drug 
candidates electron rich hydroxylamine represents the active form of the drug to be 
effective in tumor cells.32 The first nitro imidazole aziridine containing agent RSU1069, 
5, explored hypoxia selective, redox activated generation of an alkylating agent.33 Similar 
nitro-imidazole-containing mustards such as RB6145 6 and 5 were tested in tumor cells.34 
In addition to mustard-type alkylating agents, DNA intercalating moieties such as 
7 
 
acridine 7 and quinoline 8 groups were used as bio reductively activated agents. Upon 
bio-reduction, the intercalating ability of amine compounds of 7 and 8 is enhanced to 
cause interferences during DNA replication (Scheme 1.10).35 
 
 
 
Scheme 1.10. Nitro aromatics reduction in hypoxia produces the active drug   
 Mustard groups have been attached to nitrophenyl moiety, as a continuation of 
efforts to develop nitroaryl-aziridine conjugates.36 Nitrobenzene aziridines CB 1954, 9, 
SN 23862, 10, and PR 104, 11 explore nitro reduction as the mean of mustard activation 
in tumor cells (Scheme 1.11).37 
 
 
 
 
Scheme 1.11. Nitrophenyl-mustard alkylating agents 
 The aziridine alkylating moiety would attain greater activity upon the reduction of 
nitro group to amine group under hypoxia. Specific enzymes such as E. coli 
nitroreductases has been used as the reducing enzyme under gene directed enzyme pro-
drug therapy GDEPT to test nitrobenzyl mustard 9.32 In addition, DT diaphorase has been 
used with nitrophenyl-aziridines and nitrogen mustards to test the enhanced selectivity 
toward hypoxia and improved cytotoxicity.38 In the mechanism, of which nitroaryl-
mustards attain activity, nitro compound 11 undergoes reduction to produce amine 12. 
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The increased electron density on 12 works toward the formation of alkylating aziridine 
13 (Scheme 1.12).39 
 
 
 
Scheme 1.12. Nitrophenyl-mustard alkylating agents 
1.3.2 Elimination of active agent through nitroaromatic reduction 
 The electronic properties of a molecule can undergo a major shift when a pendent 
nitro group is reduced to the respective hydroxylamine and to the amine group in hypoxia 
mediated by cellular reductases. The increase of electron density on hydroxylamine 
nitrogen has been employed release an active agent. The active drug is attached to a 
suitable nitro aromatic group in its prodrug form.40 The activity of the agent is diminished 
or masked due to the ligation with the nitro aromatic group. The structural difference of 
conjugate 14, nitroimidazole-phosphoramidate to the active agent 17, a phosphoramidate, 
may cause the reduced effect of drug.41 Once the nitro group on 14 is reduced in hypoxia, 
to the hydroxylamine group bearing 15, the enhanced electron density on nitrogen of 
hydroxylamine will eject the active agent 17, which is a good leaving group.42 This 
electron movement will trigger covalent bond scission, which releases the active drug 17 
from the pro-drug complex (Scheme 1.13) while forming imine methide 16.43 
 
 
 
Scheme 1.13. Hydroxylamine releases the active drug 
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The phosphoramidate 17 can form aziridine, which acts as an electrophile that can 
alkylate cellular nucleophiles (Scheme 1.14).  
  
 
 
Scheme 1.14. Phosphoramidate forms azide upon elimination of leaving group 
 There are number of nitroaromatic-prodrugs designed to carry phosphoramide 
toxins, structurally and functionally similar to phosphoramidate, such as 18 to cells. The 
parent cyclophosphoramide drug 18 has been widely used anti-cancer agent with 
excellent toxicity toward various tumor types.44 Although the positive results were 
encouraging, the parent cyclophosphamide showed lethal side effect, occurred due to 
release of acrolein 21 along the CYP450-mediated metabolic pathway via forming 
intermediates 19 and 20 (Scheme 1.15).45   
 
 
 
Scheme 1.15. Cyclophophoramide 18 metabolism by CYP450 
 Delivering phosphoramide, 22, selectively to tumor is considered important in 
order to avoid such toxicity reported with 18.46 The nitroquinoline-phosphoramide 
mustard 23 was developed as a pro-drug to test the ejection of phosphoramide toxin 22. 
Upon the reduction of the nitro group on quinoline, the electron rich quinoline nitrogen 
on 24 triggers beta elimination of 22 leaving 25 as a metabolite. Tenfold increase of 
cytotoxicity was observed in hypoxia and evidence for alkylation occurred by 
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phosphoramide confirmed the expected release of phosphoramide 22 upon nitro reduction 
(Scheme 1.16).40 
 
 
 
 
Scheme 1.16. Nitroquinoline-phosphoramide prodrug release  
Other nitro-aromatics nitrobenzyl, nitrofuryl and nitrothienyl have been used as 
bio-reducible triggers for conjugation with phosphoramides. These prodrugs, constructed 
from tagging phosphoramide with nitroaromatics have shown encouraging results; low 
cytotoxicity but enhanced tumor selectivity. Compound 24 generated DNA interstrand 
cross links in hypoxic HT-29 cells, with a selectivity ratio of 90.47 Nitrophenyl 26, 
nitrofuryl 27 and nitrothienyl 28 derivatives show low toxicity in aerobic assays (Scheme 
1.17).48 
 
 
 
Scheme 1.17. Nitrophenyl, Nitrofuryl and nitrothienyl phosphoramide conjugates  
 In addition to the phosphoramide mustards, various anti-cancer agents are 
conjugated to nitroaromatics. Combrestatin, 29 and its nitrothienyl couple 30, and 
nitrophenyl-mercaptopurine prodrug 31 have shown effective release of agent upon 
bioreduction (Scheme 1.18).49  
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Scheme 1.18. Nitrothienyl and nitrophenyl dimethyl prodrugs  
 The importance of nitroaromatic reduction in tumor therapy and prodrug 
designing is well established in medicinal chemistry and bioorganic chemistry. In the 
coming chapters, interesting metabolic and fluorescence studies on 6-nitroquinoline 
reduction will be discussed. Moreover, the oxygen sensitivity of 6-nitroquinoline 
reduction, under two enzymatic reducing systems will be presented. Several novel 
findings related to the 6-nitroquinoline reduction will add complexity to enzyme 
mediated nitroaromatic reduction in hypoxia. 
1.4. N-oxides  
Investigations carried out to develop radio sensitizing agents tested nitroxyl 
radical TEMPO. It has been discovered that TEMPO connects with the DNA radical, 
which is formed by radiolysis under hypoxia to produce DNA adduct 32.18 In search for 
backups to N-oxide radiosensitizing agents, Brown and coworkers tested tirapazamine 
(TPZ), N-oxide 33 as an oxygen mimetic agent in radiolysis of cells. They found that 33 
was toxic as a single agent and the cytotoxicity was 200 fold higher for hypoxic cells.50 
The anti-cancer properties shown by 33 in the absence of γ radiation was stirred interest 
and the mechanism for the anti-tumor activity of 33 has been subjected further for 
research (Scheme 1.19).51  
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Scheme 1.19. N-oxide radiosensitizing agents 
 TPZ is believed to be activated by enzyme systems such as cytochrome P450 and 
cytochrome P450 reductase, xanthine and xanthine oxidase, aldehyde oxidase and nitric 
oxide synthase in cells.52 The activation produces a TPZ radical which back oxidizes to 
the parent TPZ by oxygen under aerobic conditions to produce superoxide radical.23, 50, 53 
The superoxide radical disproportionate to yield hydrogen peroxide by super oxide 
dismutase (SOD) and hydrogen peroxide is converted to water and hydroxide ion by 
catalase (CAT).23 Unless the superoxide radical is handled consecutively by SOD and 
CAT, radical-mediated oxidative damage may occur to biomolecules.23 Under hypoxia, 
the TPZ radical 34 persists and produces an oxidizing radical which cause DNA 
damage.51, 54 The in vivo enzymatic reduction process produces metabolites 35, the major 
metabolite and 36 (Scheme 1.20).55 
 
 
 
 
Scheme 1.20. Enzyme mediated reduction of 33 in hypoxia 
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The DNA damage resulted by TPZ in hypoxia is believed to cause cytotoxicity in 
tumors.56 The mechanism of TPZ-mediated DNA damage is not properly understood.57 
There are three mechanisms proposed to describe the nature of the DNA damaging 
species.58  
 The neutral benzotriazine dioxide radical 34, formed from 37 upon enzymatic 
reduction of 33 has been proposed by Brown’s group as the oxidizing species which 
causes the DNA damage.59 In this proposal, a proton on DNA is abstracted by 34 to form 
38. A dehydration event proceeds via 38 to release water and 35 (Scheme 1.21).60 
 
 
 
Scheme 1.21. Enzyme mediated reduction of 33 in hypoxia abstract proton from DNA, followed by 
dehydration releases 35 as the major metabolite 
Alternatively, a homolytic bond scission of N-OH bond in neutral benzotriazine 
dioxide radical 34 can form a hydroxyl radical and the major metabolite 35 (Scheme 1.22 
upper arm).61The hydroxyl radical, released from 34 is capable of performing oxidative 
damage on DNA.62 Oxidative DNA damage occurs in tumor cells can initiate a cascade 
of events which result in cytotoxicity.63 Denny and co-workers suggest a mechanism 
based on dehydration that might occur on the neutral benzotriazine di-oxide radical 34 
forms a benzotriazinyl 1-oxide radical (structures 39, 40 and 41) which is responsible for 
the DNA damage (Scheme 1.22 lower arm).64 
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Scheme 1.22. The enzyme mediated reduction of 33 in hypoxia may produce hydroxyl radical or 
benzotriazine radicals 39, 40 or 41 as the oxidizing species 
 Research carried out by our group support the mechanism involving hydroxyl 
radical mediated DNA damage.65  
1.5. Summary  
 Nitroaromatic compounds have become a prominent drug class in medicinal 
chemistry research.66 The nitroaromatic reduction that occurs in low oxygen 
concentrations is mediated by reductive enzymes and has become an attractive concept in 
bioreductive prodrug therapy.58 Nitroaromatic reduction reactions are complex due to the 
presence of various intermediates and byproducts.67 The work presented in this thesis 
describes the use of small molecule 6-nitroquinoline as a fluorescent probe that can detect 
hypoxia.68 A rich metabolic study is accompanying the fluorescent results in coming 
chapters. In addition the lead N-oxide tirapazamine, which has been in phase trials І, ІІ 
and ІІІ for clinical therapy over a decade and its analogs were used to study the DNA-
15 
 
damaging mechanism of N-oxides.69 The chemical basis for the DNA damage, caused by 
33 depends on the reduction mechanism of these di-oxide.65 The chemical nature of the 
DNA-damaging species has become an interesting topic in research. In the current thesis, 
a mechanistic study is presented analyze the reduction mechanism and the chemical 
nature of the oxidizing species.  
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Chapter 2  
Hypoxia-selective, enzymatic conversion of 6-nitroquinoline into a 
fluorescent helicene: pyrido[3,2-f]quinolino[6,5-c]cinnoline 3-oxide 
2.1 Hypoxia as a parameter to be determined qualitatively and quantitatively.   
 
 Hypoxia or low oxygen concentrations exist in disease conditions such as 
ischemia, stroke, inflammation and solid tumors, and in normal human physiology.1 
Transient regions of hypoxia, reportedly present in stem tissues may have an effect on 
controlling cell division and differentiation during hematopoiesis and embryogenesis.2 
 Oxygen concentration in a normal healthy cell is within a range of 20 to 90 µM 
(14–65 mm Hg).3 Any concentration below 20 µM is considered hypoxia.4 Efforts were 
made to quantify hypoxia using an oxy probe, radiochemical imaging and 
immunohistochemical staining methods.5 Practical and technical difficulties limit 
accuracy and applicability of these techniques.6 Hence, there is a demand for a 
noninvasive tool which can qualitatively and quantitatively characterize tumor hypoxia in 
biological conditions. Fluorescent probes can be designed to light up inside the hypoxic 
tumor under physiological conditions, and the fluorescence outcome can be used as a 
parameter that can be measured and relate to the oxygen concentration of tumors.7 
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2.2 Fluorescent probes to detect hypoxia 
 
 
Several approaches have been used to deliver a fluorescent agent into the tumor 
setting to mark hypoxic tissues. One method is to use nitro-aromatic non-fluorescent 
compound which converts to a fluorescent amino metabolite under hypoxic conditions.7-8 
Enzyme mediated cellular reduction of nitroaromatics, under low oxygen levels, has been 
reported and developed as a concept in biochemical research. The reduction process 
consists of consecutive addition of six electrons, in a stepwise manner to produce the 
final reduced product, the respective arylamine.9 The hypoxia selectivity arises within the 
first reduction step where the nitro radical anion back-oxidizes to the parent nitro 
compound in the presence of oxygen.9d, e, 10 The first electron addition step is oxygen 
sensitive and the remaining one electron addition steps may be oxygen sensitive. Niroso 
compound would next be converted to hydroxylamine intermediate by adding two 
electrons and in the final two electrons addition produces the amino product. (Scheme 
2.1).11 
 
 
Scheme 2.1. Enzymatic reduction profile of nitroaromatic compound  
2.3 Reduction of 42 to obtain 43 under anaerobic conditions 
Non-fluorescent nitroaromatic compound 6-nitroquinoline 42 was used as a small 
molecule nitroaromatic probe to detect hypoxia. The compound 42 may be reduced under 
low oxygen levels and under bio-reductive conditions to produce fluorescent metabolite, 
6-aminoquinoline (43, Scheme 2.2)  
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Scheme 2.2. Hypoxic metabolism of 42 is expected to form fluorescent 43 
The amino compound 43 is a known fluorescent molecule and the reduction of 42 
to 43 step yields a good Strokes shift of 205 nm.12 The probe 42 is non-fluorescent in 
aqueous sodium phosphate buffer at pH 7.4 (Figure 1A, column 1).11 The enzyme 
NADPH:cytochrome P450 reductase, a known reductase that reduces nitrocompounds in 
cells is used as the reducing enzyme with assistance of the substrate NADPH to reduce 
42 under hypoxia.9c, 13 The hypoxic reduction reaction forms fluorescence with an 
impressive 63-fold increase at 445 nm, indicating conversion of the non-fluorescent 42 to 
a fluorescent metabolite (Figure 1A, column 5). The enzymatic reduction of 42 under 
aerobic conditions produced no fluorescence (Figure 1A, column 4). Similarly, when non 
fluorescent electron acceptor benzotriazine 1,2,4-di-oxide was used in aerobic and 
anaerobic enzymatic reduction reactions, very low fluorescence was observed (Figure 
1A, columns 2 and 3). Careful inspection of the shape of the fluorescent curve in Figure 
1, column 5 showed that the fluorescence emission curve does not resemble the 
fluorescence curve of authentic 43. The fluorescence emission curve of 43 is broader at 
445 nm and 530 nm regions (Figure 1B blue line) and, instead consists of a pair of 
emission maxima at 440 and 460 nm. The unexpected fluorescence, yielded in the 
hypoxic metabolism of 42, was explored to identify and characterize the fluorescent 
metabolite. 
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Figure 2.1. Enzymatic conversion of 42 into a fluorescent product under hypoxic conditions. A. 
Fluorescence emission at 445 nm (λex 307 nm) for:  (1) a control sample of compound 42 alone (0.8 mM), 
(2) a control reaction composed of NADPH:cytochrome P450 reductase (1.1 U/mL), NADPH (2.4 mM), 
and a non-fluorescent electron acceptor 1,2,4-benzotriazine 1,4-dioxide (6.4 mM) under aerobic conditions, 
(3) a control reaction composed of NADPH:cytochrome P450 reductase, NADPH, and a non-fluorescent 
electron acceptor 1,2,4-benzotriazine 1,4-dioxide (6.4 mM) under anaerobic conditions, (4) compound 42 
(0.8 mM) + NADPH:cytochrome P450 reductase and NADPH under aerobic conditions, (5) compound 42 
(0.8 mM) + cytochrome P450 reductase and NADPH anaerobic.  Reactions were incubated for 18 h in 
sodium phosphate buffer at (12 mM, pH 7.4) at 24 ˚C, then diluted with aerobic sodium phosphate buffer 
(12 mM, pH 7.4) and the fluorescence measured (λex 307 nm, λem 445 nm). It is important to note that 
NADPH exhibits fluorescence with an emission maximum at 445 nm. However, control experiments 
showed that any NADPH left unconsumed at the end of the anaerobic reactions described here is ultimately 
converted to the non-fluorescent NADP+ product by enzyme-driven redox cycling of the electron accepting 
organic substrate upon opening the reaction vessel to air and dilution with aerobic buffer prior to 
fluorescence measurements. B. Fluorescence spectrum of the reaction mixture generated in the anaerobic 
metabolism of 42 by NADPH:cytochrome P450 reductase as described for reaction 5 above (orange line, 
with emission maxima at 440 and 450 nm) and fluorescence spectrum of 6-aminoquinoline (43, 50 µM, λex 
340 nm, in sodium phosphate buffer, 10 mM, pH 7.4).11 
 
 
2.4 Identification of products arising from the anaerobic reaction  
 
 
The anaerobic reaction mixture of metabolism of 42, mediated by 
NADPH:cytochrome P450 reductase was analyzed using LC/MS. Two major products 
were identified in addition to the remaining starting material 42 (Figure 2.2 A). 
Confirming the analysis of the fluorescence spectrum of the anaerobic reaction mixture, 
43, the product expected by the original six electron reduction process was not observed 
in the LC/MS analysis. Under the same LC/MS conditions 43 appears at approximately 
4.5 min (Figure S1). One of the products, eluting at 19.4 min in the UV trace has m/z 
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value of 301 (Figure 2.2 B). The [M+H]+ ion of 6,6’-azoxyquinoline would have a mass-
to-charge ratio of 301 (45, Scheme 2.2). Formation of 45 under relevant conditions is 
expected to be produced, based on precedents which suggest condensation of 
intermediates 6-nitrosoquinoline and 6-hydroxylaminoquinoline that are formed along the 
reduction path.14 An authentic sample of 45, synthesized from reducing 42 by hydrazine 
hydrate in the presence of Raney nickel gave similar LC/MS spectra with a peak at 19.4 
min (Figures 2.2 E and F).15 Compound 45 is non-fluorescent under the applied 
conditions in the solution. Hence the fluorescence should arise from the product 
appearing at 15 min in the LC trace. There is evidence that complex dimmers such as 44 
could be fluorescent.16 The mass-to-charge ratio of the new product was 299 (Figure 2.2 
C). A simple, quinoline dimer such as azoxy or azo does not have a m/z of 299, rather a 
more complex quinoline-based bi aryl compound such as pyrido[3,2-f]quinolino[6,5-
c]cinnoline 3-oxide (44, Scheme 2.3) or dipyrido[3,2-a:3',2'-h]phenazine 7-oxide (46, 
Scheme 2.3) does have the observed m/z value. 
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Figure 2.2. LC/MS analysis of the reaction mixture generated by anaerobic metabolism of 42 (0.8 mM) by 
cytochrome p450 reductase (1.1 U/mL) and NADPH (6.4 mM).  The enzymatic reduction of 42 was carried 
out as described in the experimental section and the legend of Figure 2.1. The reaction was dried and 
products dissolved in methanol. The mixture was eluted with a gradient of 99% A (water containing 0.1% 
acetic acid) and 1% B (acetonitrile containing 0.1% acetic acid) followed by linear increase to 90% B over 
30 min. The elution was continued at 90% B for 3 min and then B was decreased to 1% over next 8 min. A 
flow rate of 0.35 mL/min was used and the metabolites were detected at 254 nm. Mass spectra were 
obtained using electrospray ionization in the positive ion mode. Panel A: HPLC of the anaerobic reaction 
mixture monitoring absorbance at 254 nm.  Panel B:  LC/MS spectrum of the product eluting at 19.1 min.  
Panel C: LC/MS spectrum of the product eluting at 15.1 min.  Panel D: LC/MS spectrum for of the product 
eluting at 17.1 min. Panel E: HPLC retention time of authentic 45 monitoring absorbance at 254 nm. Panel 
F:  LC/MS spectrum of authentic 45. Panel G: HPLC retention time of authentic 44 monitoring absorbance 
at 254 nm. Panel H:  LC/MS spectrum of authentic 44. 
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Scheme 2.3. Metabolites formed by the reduction of 42 with NADPH/CYP450R 
According to precedents, helicenes are structurally similar to 44, and are 
fluorescent.16 Hence, the enzymatic reduction of 42, under above condition might be 
producing 44.The two structures 44 and 46 have same molecular formula. Huisgen 
proposed that compound 44 is formed in a reaction when 42 is reduced by sodium 
methoxide.17 Farrar claimed that Huisgen was obtaining compound 46, not 44.18 
Moreover, Farrar carried out reduction of 42, with alkaline glucose as suggested by 
Galbraith et al to produce 45. Farrar claimed that alkaline glucose mediated reduction of 
42 actually produces 44 not 45.18  
2.4 Synthesis and structural characterization of 44 
 
Galbraith’s alkaline glucose reduction of 42 has been successfully used as the 
chemical method to synthesize 44.19 The thin layer chromatographic (TLC) properties of 
the product of enzymatic reduction of 42 are compared with that of the product, obtained 
by the chemical synthesis. The blue fluorescent product showed similar migration with 
different solvent systems on TLC, suggesting two different reactions produce the same 
chemical product. Hence, we separated the suspected product from the chemical 
synthesis by preparative TLC and carried out full spectroscopic characterization (see 
materials and methods). The molecular formula obtained from a high-resolution mass 
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spectrometric analysis of product, formed by alkaline glucose reduction of 42, matches 
with structures 44 or 46. Presence of 18 different 13C resonances suggested that the 
dimmer is not symmetric, but rather contains a complex asymmetric structure. The 1H 
NMR analysis showed ten hydrogen resonances; aryl-aryl bridge between two quinoline 
molecules might be present in the structure. The 5 proton of 46 was expected to be 
downfielded to ≥ 9.3 ppm due to its proximity to the N-oxide oxygen (We used a 
quinolone based numbering system in the section).20 In the product, a resonance at 9.3 
ppm is absent. The fluorescence of enzymatic metabolite and NMR properties are 
supportive of 44 as the possible structure for the metabolite. Moreover, COSY and 
TOCSY spectra analysis allowed assigning resonances for 4 and 4’ protons for structure 
44. NOE experiment results showed a correlation between 4 and 4’ protons that arises 
due to close proximity between two protons. The NOE correlation between 4 and 4’can 
be only present in 44. In 46, the protons 4 and 4’ are unable to produce NOE resonance. 
Ultimately, the actual structure obtained from alkaline glucose reduction of 42 shows the 
distance between protons 4 and 4’ is 2.5 Å (Figure 4).  
The NMR data obtained from the enzymatically synthesized 44 was compared with the 
NMRs of chemically synthesized 44. The 1H NMR resonances and peak shifts obtained 
from the enzymatic reaction matched with that obtained from the glucose reduction. NOE 
spectrum of the enzymatic product shows a correlation between 4 and 4’ protons, similar 
to the NOE result obtained from the glucose reduction. This observation confirms that 
product 44 is the metabolite produced in the anaerobic enzymatic reaction. The complete 
NMR analysis including TOCSY, COSY, HMQC, and HMBC data were consistent with 
the azoxy-helicene 44 (Table 1).  
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position δC δH (J in Hz) COSY TOCSY HMBCa NOE 
2’ 153.4 9.15 1H, d 
(4.5) 
3’ 3’, 4’ 4’, 8a’ 3’ 
2 151.5 9.05 1H, m 3 3, 4 4, 8a 3 
3’ 120.5 7.46 1H, dd 
(9.0, 4.5) 
2’, 4’ 2’, 4’ 4a’ 2’, 4’ 
3 120.7 7.41 1H, dd 
(9.0, 4.5) 
2, 4 2, 4 4a 2, 4 
4’ 136.0 8.87 1H, d 
(9.0) 
3’ 3’, 2’ 2’, 8a’ 4 
4 134.8 8.67 1H, d 
(9.0) 
3 3, 2 2, 8a 4’ 
5’ 128.0      
5 114.2      
4’a 123.4      
4a 123.5      
7’ 121.8 9.05 1H, m 8’ 8’ 8a’, 5’ 8’ 
7 127.4 8.23 1H, d 
(9.0) 
8 8 8a, 5 8 
8’ 133.4 8.43 1H, d 
(9.0) 
7’ 7’ 6’, 4a’ 7’ 
8 134.3 8.41 1H, d 
(9.0) 
7 7 6, 4a 7 
6’ 137.1      
6 144.1      
8’a 149.7      
8a 148.5      
Table 1. NMR Data (CDCl3) for compound 44aHMBC correlations are from the proton to the 
stated carbon(s). 
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The ultimate confirmation of the structure 44 was carried out by X-ray 
crystallographic analysis (Figure 2.3).21  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. In 44, the 4 and 4’-hydrogens (see numbering system in Scheme 2.2) are close in space11 
 
 
In summary, the spectroscopic and crystallographic characterization of 44 arising 
from the alkaline glucose reduction is consistent with Farrar’s claim; 44 produced in the 
alkaline glucose reduction of 42. More importantly 44, produced by alkaline glucose 
method used as an authentic compound for comparison with the enzymatically produced 
44. LC/MS properties of 44, produced under chemical and enzymatic methods showed 
matching retention times and m/z results (Figure 2.2). The 1H NMR analysis of the 
enzyme product resembles the authentic compound 44, made by the glucose reduction 
reaction. In addition, NOE experiment clearly shows the close distance between 4 and 4’ 
protons of enzymatically-generated 44. The fluorescence spectrum of 44, obtained from 
the glucose reduction (Figure 2.4) resembles the fluorescence spectrum obtained from the 
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enzymatic reaction (Figure 2B). Close analysis of the spectra shows the similarity of 
emission maxima at 440 and 460 nm of both curves (Figure 2.1 and 2.4).  
  
 
 
 
 
 
 
Figure 2.4. Fluorescence spectrum of authentic 45 (50 µM, λex 307 nm) in sodium phosphate buffer (12 
mM, pH 7.4). 
 
The azoxy functional group is known to be reduced to the corresponding azo 
group by NADPH:cytochrome P450 reductase.22 In this particular reaction compound 45 
is not reduced to an azo product. 
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Scheme 2.4. Mechanism for the formation of 44 under anaerobic conditions 
 
2.5 Conclusion 
 
In conclusion, intermediate hydroxylamino or amino product were not observed 
in NADPH:cytochrome P450 reductase mediated reduction of 42 under hypoxic 
conditions. The azoxy compound 45 and the bi aryl bonded dimer 44 were formed under 
reductive conditions. The mechanism for the formation of 44 in the enzymatic reaction is 
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complex. A possible pathway can be initiated when a nitroaryl radical 47 and a 
nitrosoaryl radical 48 are condensed to form a bi aryl bond to connect two quinolone 
groups and then tautomerization occurs toward an intramolecular condensation between 
hydroxylamine and nitroso moieties to produce 44 (Scheme 5).  
Nitro aryl compounds are good candidates to selectively label hypoxic cells using 
fluorescence under bio-reductive conditions.8a, 23 Many probes have been synthesized but 
the products resulting from the bioreduction have not been characterized.7a, 23a, 24 Our 
work underlines the importance of characterization of complex metabolites that can arise 
in these reduction reactions of nitro-aromatic probes.  
 
2.6 Experimental 
 
Materials and methods.  Materials were purchased from following sources: NADPH, 
cytochrome p450 reductase, sodium phosphate, DMF, glucose, Raney nickel slurry in 
water, silica gel (0.04-0.063 mm pore size) for column chromatography, and silica gel 
plates for thin layer chromatography from Sigma chemical company (St. Louis, MO); 6-
nitroquinoline, 6-aminoquinoline, and hydrazine hydrate from Alfa-Aesar (Ward Hill, 
MA); ethyl acetate, hexane, dichloromethane, methanol, ethanol, HPLC acetonitrile and 
HPLC water from Fischer; Deuterated NMR solvents were from Cambridge Isotope 
Laboratories (Andover, MA). The compound 1,2,4-benzotriazine-1,4-di-N-oxide was 
synthesized according literature methods.1  High resolution mass spectrometry (HRMS) 
analyses were performed at the mass spectroscopy facility of the University of Illinois 
Champaign-Urbana and low resolution mass spectroscopic analyses were carried out at 
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the University of Missouri-Columbia.  1H and 13C NMR experiments and were done on a 
Bruker Avance DRX300 with 5 mm broadband probe and Bruker Avance DRX500 with 
CPTCI probe using deuterated NMR solvents methanol (CD3OD) and 
chloroform(CDCl3) at the University of Missouri-Columbia.  The reference peaks were 
set to 3.31 ppm and 49.00 ppm for deuterated methanol and 7.26 ppm and 77.00 ppm for 
deuterated chloroform from tetramethylsilane for the 1H and 13C spectra respectively.  
The fluorescence spectra were obtained on a Varian Cary Eclipse Fluorescence 
Spectrophotometer equipped with xenon flash lamp with instrumental slit width settings 
at 10 nm employing a 10 mm path length quartz cuvette. 
Procedure for hypoxic metabolism.  
In a typical enzymatic reaction, 42 ( 4 µL from 50 mM in DMF, final concentration 0.8 
mM) or non-fluorescent electron acceptor (24 µL from 50 mM in 15 % DMF water, final 
concentration 6.4 mM), was mixed with NADPH (20-160 µL of 10 mM, final 
concentration 0.8 mM-6.4 mM), cytochrome p450 reductase (2 µL from 140 U/mL, final 
concentration 1.1 U/mL), sodium phosphate buffer (6 µL from 50 mM, final 
concentration 12 mM, pH 7.4) and HPLC water to obtain the final solution (0.25mL, less 
than 2% DMF) at room temperature (240C). For anaerobic reactions, all reagents except 
NADPH and cytochrome p450 reductase were de-gassed in glass tubes by three freeze 
pump thaw cycles. The glass tubes were broke open inside an argon purged glove bag 
and bubbled with argon for five minutes. Solid NADPH was dissolved in HPLC water to 
make stock solution inside the glove bag and cytochrome p450 reductase was used as is 
from the original sample from the supplier. Upon mixing, the containers were wrapped 
with aluminum foil to prevent exposure to light.  
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Procedure for Fluorescence experiment 
Upon completion of incubation reaction solution was diluted up to 1 mL with 
sodium phosphate buffer (50 mM, pH 7.4) in HPLC water, and then was added to the 
cuvette. In anaerobic experiments, upon completion the reaction mixtures were taken out 
of glove bag and kept 1 h under atmospheric conditions prior to the dilutions.  
Procedure for LC/MS analysis.   
In vitro enzymatic metabolism of 42 was carried out as described above, and the 
resulting products were extracted into ethyl acetate and dried using brine followed by 
roto vap evaporation of ethyl acetate.  The solid was re-dissolved in methanol and 
analyzed by LC/MS in the positive ion mode.  Separation of metabolites was carried 
using a C18 reverse phase Phenomenex Luna column (5 µm particle size, 100 A0 pore 
size, 150 mm length, 2.00 mm i.d.) and a ThermoSeparations liquid chromatograph 
(TSP4000), the metabolites were detected by their UV-absorbance at 254 nm.  The 
elution started with a gradient of A, 99% HPLC water (0.1% acetic acid) and B 
acetonitrile (0.1% acetic acid) followed by a linear increase to 90 % B over the course of 
30 min.  The elution was continued at 90% B for 3 min and decreased to 1% over the 
next 8 min.  A flow rate of 0.35 mL/min was used.  The LC/ESI-MS analyses were 
carried out in the positive ion mode on a Finnigan TSQ 7000 triple quadrupole instrument 
using a 250 kV needle voltage and at a capillary temperature of 250 ˚C. 
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Figure S1. LC/MS analysis of 43. (A) UV chromatogram of 43, (B) LC/MS analysis of the product eluting 
at 4.6 min in the chromatogram. 
 
 
 
 
 
 
 
 
Figure S2. (A) Fluorescence spectrum of NADPH (50 µM, λex 307 nm, in sodium phosphate buffer, 10 
mM, pH 7.4). It is noteworthy that the shape of the fluorescence emission peaks of NADPH and 44 are 
distinct. (B) NADPH fluorescence diminishes over the course of 1 h when the reactions are exposed to 
aerobic conditions. Reactions contained 42 (0.8 mM), NADPH:cytochrome P450 reductase (1.1 U/mL), 
and NADPH ( 3 mM) in sodium phosphate buffer, 10 mM, pH 7.4 (λex 307 nm, λem 460 nm). Reactions 
described here were incubated quenched with aerobic buffer and incubated for approximately 1 h before 
fluorescence analysis. Thus, the control experiment provides evidence that fluorescence detected in the 
metabolism of 42 is not due to residual NADPH. 
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Figure S3. Fluorescence emission at 445 nm (λex 307 nm) for reactions: compound 42 (0.1-0.8 mM) + 
NADPH:cytochrome P450 reductase (1.1 U/mL), NADPH (0.1-0.8 mM) under anaerobic(blue) and aerobic 
(red), and a non-fluorescent electron acceptor 1-methyl-2-nitro-5-carbethoxyimidazole (0.1-0.8 mM) + 
NADPH:cytochrome P450 reductase (1.1 U/mL), NADPH (0.1-0.8 mM) under anaerobic (green) and 
aerobic (purple). Reactions were incubated for 18 h in sodium phosphate buffer at (12 mM, pH 7.4) at 24 
˚C, then diluted with aerobic sodium phosphate buffer (12 mM, pH 7.4) and the fluorescence measured 
(λex 307 nm, λem 445 nm).  It is important to note that NADPH exhibits fluorescence with an emission 
maximum at 445 nm.  However, control experiments showed that any NADPH left unconsumed at the end 
of the anaerobic reactions described here is ultimately converted to the non-fluorescent NADP+ product by 
enzyme-driven redox cycling of the electron accepting organic substrate upon opening the reaction vessel 
to air and dilution with aerobic buffer prior to fluorescence measurements.   
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Synthesis of 1,2-di(quinolin-6-yl)diazene oxide (45). We employed a variation on the 
literature procedure of Boge et al.2 To a solution of compound 42 (0.5 g, 2.87 mmol) in a 
mixture of EtOH:CH2Cl2 (1:1, 20 mL) at 0 ˚C in an ice/salt bath was added Raney nickel 
slurry (0.5 mL, active catalyst in water, Sigma-Aldrich cat. number 221678).  To this 
mixture, hydrazine hydrate (1.5 mL, 30 mmol) portions were added over the course of 3 h 
with stirring until 42 was consumed (TLC) and the resulting mixture stirred overnight. 
The solid was removed by filtration and the resulting solution dried by extraction with 
brine and then over sodium sulfate.  The compound was purified by column 
chromatography on silica gel eluted with ethyl acetate in the first column separation and 
second column chromatography separation on silica gel was done with MeOH:CH2Cl2 
(99:1) to obtain 45 , a yellow solid, in pure form (100 mg, Rf value = 0.25 in 4% MeOH 
in CH2Cl2) 1H NMR (CDCl3, 300 MHz): δ ppm 9.14 (d, J = 2.5 Hz, 1H), δ 9.00 (dd, J = 
4.5 Hz, J = 1.5 Hz, 1H), δ 8.93 (dd, , J = 4.5 Hz, J = 1.5 Hz, 1H), δ 8.82 (d, J = 2.5 Hz, 
1H), δ 8.67 (d, J = 9.0 Hz, 1H), δ 8.31 (dd, J = 9.0 Hz, J = 1.5 Hz, 1H), δ 8.21 (m, 4H), δ 
7.49 (dd, J = 8.5 Hz,  J = 4.5 Hz, 1H), 7.42 (dd, J = 8.5 Hz, J = 4.5 Hz, 1H), 1.23 grease. 
13C NMR (CDCl3, 75.5 MHz): δ 152.86, 151.97, 149.64, 148.72, 146.01, 141.93, 137.88, 
137.76, 130.95, 130.32, 129.32, 128.46, 127.73, 123.76, 123.40, 122.68, 122.64, 122.09; 
HRMS (ESI, [M+H]+) m/z calcd for C18H13N4O 301.1089, found 301.1080. 2Boge, N.; 
Kruger, S.; Schroder, M.; Meier, C.; Synthesis 2007, 24, 3907-3914. 
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Figure S3. 1H NMR of 45 (CDCl3, 300 MHz) 
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Figure S4. 13C NMR of 45 (CDCl3, 75.5 MHz) 
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Preparation of pyrido[3,2-f]quinolino[6,5-c]cinnoline 3-oxide (44) via alkaline 
glucose reduction of 42.3  A solution of 42 (1.0 g, 5.61 mmol) in NaOH (20% aqueous 
solution, 10 mL) and was heated to 90 ˚C with stirring.  To this solution, D-(+) glucose 
(1.3 g, 7.21 mmol) was added over 30 min and stirred for 1 h.  The mixture was extracted 
with EtOAc (20 mL) and the combined organic extracts washed with brine and dried over 
magnesium sulfate.  The mixture separated by column chromatography on silica gel and 
eluented with ethyl acetate and MeOH (99:1) to obtain the helicene 44, a yellow 
solid(300 mg, 18% yield). 1H NMR (CDCl3, 500 MHz,): δ 9.15 (d, J = 4.5 Hz 1H), 9.05 
(m, 2H), 8.87 (d, J = 9.0 Hz, 1H), 8.67 (d, J = 9.0 Hz, 1H), 8.44 (d J = 9.0 Hz, 1H), 8.40 
(d J = 9.0 Hz, 1H), 8.23 (d, J = 9.0 Hz, 1H), 7.46 (dd, J = 9.0 Hz, J = 4.5 Hz, 1H), 7.41 
(dd, J = 9.0 Hz, J = 4.5 Hz, 1H). 13C-NMR (CDCl3, 125.8 MHz,): δ 153.35, 151.47, 
149.71, 148.53, 144.08, 137.09, 136.02, 134.79, 134.28, 133.41, 128.00, 127.45, 123.52, 
123.34, 121.75, 120.56, 120.46, 114.21; HRMS (ESI, [M+H]+) m/z calcd C18H11N4O 
calculated mass 299.0933; actual mass 299.0934 Crystals for X-ray analysis were 
obtained by dissolving the pure compound in minimum amount of warm MeOH, 
followed by slow evaporation (3 d) in a 2 mL vial. 
3Galbraith, H. W.; Degering, E. F.; Hitch, E. F. J. Am. Chem. Soc. 1951, 73:1323 
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Figure S5. 1H NMR of 44 (CDCl3, 500 MHz) 
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Figure S6. 1H NMR of 44 aromatic region (CDCl3, 500 MHz) 
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Figure S6. 13C NMR of 44 (CDCl3, 125.77  MHz) 
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Figure S7. 1H–1H TOCSY of 44 (CDCl3, 500 MHz) 
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Figure S8. 1H–1H COSY of 44 (CDCl3, 500 MHz) 
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Figure S9. 1H–13C HMQC of 44 (CDCl3, 500 and 125.77 MHz): 
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Figure S10. 1H–13C HMBC of 44 (CDCl3, 500 and 125.77 MHz): 
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Figure S11. 1H-1H NOESY of 44 (CDCl3, 500 MHz): 
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Enzymatic generation of pyrido[3,2-f]quinolino[6,5-c]cinnoline 3-oxide (44)  
Compound 42 (50 mM, in 0.2 mL DMF) was mixed with sodium phosphate buffer (0.3 
mL, 10 mM, pH 7.4) and water (12.0 mL) in an argon-purged glove bag and the solution 
purged with argon (20 min).  To this mixture was added NADPH (25 mg, 0.033 mmol) 
and NADPH:cytochrome P450 reductase (0.03 mL of a 0.35 U/mL solution).  The 
resulting mixture was stirred inside the argon-filled glove bag for 18 h. The reaction was 
then extracted with ethyl acetate (20 mL), the combined organic extract washed with 
brine and dried with magnesium sulfate.  Column chromatography on silica gel eluted 
with ethyl acetate and MeOH (99:1), followed by preparative TLC eluted with ethyl 
acetate and MeOH (99:1) gave 4 (five reactions combined to yield 0.300 mg, 2% yield). 
The 1H-NMR and LC/MS properties of this material matched that of authentic 44 
prepared as described above. 
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Figure S12. 1H NMR of 44 (CDCl3, 500 MHz), obtained from NADPH and 
NADPH:cytochrome P450 reductase mediated synthesis  
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Figure S13. 1H-1H NOESY of 44 (CDCl3, 500 MHz), obtained from NADPH and 
NADPH:cytochrome P450 reductase mediated synthesis  
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Chapter 3  
Hypoxia-selective enzymatic conversion of 6-nitroquinoline to the 
fluorescent product, 6-aminoquinoline 
 
3.1 Hypoxia is an attractive target to develop fluorescent probes 
Studies carried out on tumor physiology suggested that solid tumors contain low 
oxygenated areas (hypoxic regions).1 Irregular vascularization, present inside tumors 
causes hypoxic conditions.2 Further research, conducted on hypoxia over decades had 
established the importance of hypoxia in tumor biology.3 Hypoxia selects for malignant 
phenotypes, which are unable to undergo apoptosis and result in poor prognosis.4 
Moreover, hypoxic regions contain cancer stem cells which can differentiate and cause 
metastases.5 Hence, hypoxic regions are considered as targets of interest in tumor 
biology. Fluorescent based probing agents may be useful to mark low oxygenated 
regions.6 Organic compound which can produce fluorescent response, selectively within 
tumor, may select as a candidate fluorescent probe for detecting hypoxic tumors.  
 
3.2 Fluorescent Probes to Detect Hypoxia 
 
Nitroaryl groups can undergo enzyme mediated reduction in hypoxia.7 The final 
product of the reduction process is hydroxyl amine and/or amine.8 Under normal 
oxygenated conditions, single electron reduced nitro radical gets back oxidized to nitro 
group.9 Hence the first reduction step is oxygen sensitive. 7d, 10 This sensitivity has been 
exploited by nitroaromatic prodrugs to spare normal oxygenated cells.11 Nitro-based 
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anticancer prodrugs are selectively toxic to low-oxygenated tumors and that may be due 
to the oxygen-sensitive reduction of nitro group.12 These prodrugs have been further 
tested for their oxygen sensitivity and enzymatic activation in hypoxia.11 Nitro-based 
agents which are used to mark hypoxic regions in radio imaging and 
immunihistochemical staining techniques.13 Along with these methods, nitro-based 
fluorescent probes would provide an attractive mean to visualize low oxygenated 
regions.6a, b, 14 In the designing step, a non-fluorescent nitroaromatic compound can be 
selected as a fluorescent probe when the respective amino compound is fluorescent. In 
addition, these probes should be substrates for cellular reductases, which can supply 
electrons to nitro-amine reduction (Scheme 3.1). 
 
 
 
Scheme 3.1. Enzymatic reduction steps of a typical nitroaromatic compound 
Based on this strategy, non-fluorescent 6-nitroquinoline (42) is tested as a 
nitroaryl fluorescent probe to detect hypoxia.15 In addition, a metabolic study is carried 
out to identify fluorescent and non-fluorescent metabolites. Under hypoxia, a reductive 
metabolism of 42 can be reduced to 6-aminoquinoline (43, Scheme 3.2), which is a 
known fluorophore used in biochemical assays.16 The production of non-fluorescent 
dimer 6,6’-azoxyquinoline 45 also can be anticipated (Scheme 3.2). Moreover, 205 nm 
stokes shift can be obtained by the reduction assay.16d  
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Scheme 3.2. Hypoxic metabolism of 42 forms fluorescent 43 
Similar hypoxic metabolism of 42 by NADPH:cytochrome P450 reductase 
(CYP450R) produced 45 and fluorescent helicene, pyrido[3,2-f]quinolino[6,5-c]cinnoline 
3-oxide (44, chapter 1 scheme 3.3).15 The anticipated fluorescent product 43 was not 
produced by the reducing system CYP450R (Scheme 3.2). Alternatively, another 
enzymatic reducing system xanthine and xanthine oxidase may be used to test 
metabolism of 42 in hypoxia. 
 
 
 
 
 
 
 
 
 
Scheme 3.3. CYP450R mediates conversion of 42 into fluorescent metabolites  
 
Xanthine and xanthine oxidase system is known to reductively activate bio 
reducible compounds and conduct one electron reduction under hypoxic conditions.17 
Accordingly, hypoxic conditions were applied to solutions, by conducting three cycles of 
freeze-pump-thawing.18 The deoxygenated reaction solutions, 42 and reducing system 
were mixed inside an argon purged glove bag. The compound 42 is non-fluorescent in 
solutions. Anaerobic incubation of 42 with xanthine and xanthine oxidase produced 12-
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fold fluorescence increase at 530 nm (Figure 3.1A, purple column). When xanthine 
concentration is increased, emission at 530 nm is increased. 
 
 
 
 
 
 
 
Figure 3.1 Enzymatic conversions of 42 to a fluorescent product selectively under hypoxic conditions.  A. 
Fluorescence emission at 530 nm (λex 340 nm).  Each set of assays depicted in the bar graph consists of 
(from left to right): a control sample of compound 42 alone (0.8 mM) , a control reaction composed of 
xanthine oxidase (2.4 U/mL) and xanthine (2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) under aerobic 
conditions , a control reaction composed of xanthine oxidase (2.4 U/mL) and xanthine (2.4 mM, 3.2 
mM, 4.0 mM and 6.4 mM) under anaerobic conditions , a control reaction composed of xanthine oxidase 
(2.4 U/mL), xanthine (2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) and the non-fluorescent electron acceptor, 
1,2,4-benzotriazine 1,4-dioxide,  (6.4 mM) under aerobic conditions , a control reaction composed of 
xanthine oxidase (2.4 U/mL), xanthine (2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) and the non-fluorescent 
electron acceptor, 1,2,4-benzotriazine 1,4-dioxide, (6.4 mM) under anaerobic conditions , a reaction 
composed of xanthine oxidase (2.4 U/mL), xanthine (2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) and 42 under 
aerobic conditions , a reaction composed of xanthine oxidase (2.4 U/mL), xanthine (2.4 mM, 3.2 mM, 
4.0 mM and 6.4 mM) and 42 under anaerobic conditions .  Reactions were incubated for 18 h in sodium 
phosphate buffer at (12 mM, pH 7.4) at 24 ˚C, diluted with aerobic sodium phosphate buffer (12 mM, pH 
7.4), and the fluorescence measured (λex 340 nm, λem 530 nm).  B. Fluorescence spectra of reaction 
mixtures generated in the aerobic and anaerobic metabolism of 42 by xanthine oxidase (2.4 U/mL) and 
xanthine (6.4 mM) carried out as described in the Experimental Section and fluorescence spectrum of 6-
aminoquinoline (43, 0.1 mM, λex 340 nm, in sodium phosphate buffer, 10 mM, pH 7.4). 
 
When the fluorescent emission of anaerobic 42 reduction by xanthine and 
xanthine oxidase is inspected, the shape of the fluorescent curve is clear different from 
that of 44, which is generated by the metabolism of 42 by NADPH:cytochrome P450 
reductase.15 The fluorescence curve of 44 contains two distinct emission maxima, at 440 
and 460 nm. The shape of the curve, obtained from xanthine oxidase mediated 
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metabolism of 42 resembles fluorescence spectrum of 43 (Figure 3.1B, green and red 
curves). The fluorescence intensity of aerobic reaction, containing 42, at 530 nm region, 
is low relative to the corresponding anaerobic reaction (Figure 3.10, E). When non 
fluorescent electron acceptor benzotriazine 1,2,4-di-oxide is incubated with xanthine and 
xanthine oxidase under aerobic and anaerobic conditions, low fluorescence intensity is 
detected at 530 nm region (Figure 3A, columns red and green).15 Xanthine and xanthine 
oxidase produced fluorescence, in low intensities under aerobic and anaerobic conditions 
may be due to the decomposition of cofactor of xanthine oxidase (Figure 3.10, C and 
D).19 
3.3 LC/MS analysis of the reaction mixtures generated by hypoxic metabolism of 42 
by xanthine/xanthine oxidase 
To identify metabolites, produced in the enzymatic reduction reaction we 
analyzed reaction mixtures using LC/MS. The complete LC/MS analysis includes results 
of reaction mixtures and authentic compounds (Figures 3.2 and 3.3). The anaerobic 
reaction mixture of two equivalents of xanthine shows the presence of 50 (Figure 3.2 
panels A, B and E). Compound 50 is fluorescent at 450 nm region (Figure 3.10, A). The 
contribution of 50 to the fluorescence at 530 nm region is minimal because it is unstable 
due to condensation with 49 to form 45. The mass to charge value (m/z) of M+H ion of 
peak at 3.1 min on HPLC matches with that of authentic 50 (Figure 3.3, A and B). In the 
same mixture, the m/z of M+H ion of peak at 4.5 min on the HPLC (Figure 3.2, F) is the 
same as that of the authentic 43 (Figure 3.3, C and D), consistent with the fluorescent 
results (Figure 3.1B, curves green and red). The m/z of (M+H) ion of the eluent at 5.5 
min shows 285.1, which is the M+H m/z value of 53 (Figure 3.2, A and scheme 3.4). In 
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the same reaction mixture the product eluting at 14.6 min showed m/z of 190.9 (Figure 
3.2, A and G). The authentic LC analysis of 51 is consistent with the product eluting at 
14.6 min in Figure 3.2, panel A (Figure 3.3 panels E and F). When 42 is incubated in the 
presence of xanthine oxidase, formation of 51 is possible as a metabolite along the 
reduction profile.15, 20 The product eluting at 16.4 min shows m/z value of 158.9, which is 
the M+H ion of nitroso, 49. (Figure 3.2, A, B, C and H) 
The product eluting at 19.1 min on HPLC showed m/z of 301.1 as the (M+H) ion 
(Figure 3.2 panels A and I). We employed Raney nickel mediated chemical reduction of 
42, with hydrazine hydrate to obtain 45.21 The authentic LC analysis of 45 is consistent 
with the product eluting at 19.1 min (Figure 3.3, I and J). There is no contribution to the 
fluorescence of anaerobic reactions by 45 (Figure 3.1A, purple column). The product 
appears at 24.7 min, with m/z of 282.9 may be an isomer of 52, which is not formed in 
these reactions (Figure 3.2, A and J, Figure 3.3, K and L, scheme 3.4).  
 
 
 
 
 
Scheme 3.4. Hypoxic metabolism of 42 by xanthine and xanthine oxidase  
The reaction mixture containing 2.4 mM xanthine shows diminished amounts of 
51 (Figure 3.2, B). Similarly, in 4.0 mM anaerobic xanthine assay, 51 and 50 are not 
present (Figure 3.2, C). When the xanthine amount is increase to 6.4 mM, under 
anaerobic conditions, as seen on the HPLC trace only 43, 45 and an isomer of 52 are 
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formed (Figure 3.2, D). Fluorescent product 44 is not detected in the current study 
(Figure 3.3, G and H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. LC/MS analysis of reaction mixture, generated by anaerobic metabolism of 42. Compound 42 
(0.8 mM), xanthine oxidase (2.4 U/mL) and xanthine were mixed under anaerobic conditions and the 
reaction was carried out as described in the experimental section. The reaction was dried and products 
dissolved in methanol. The mixture was eluted with a gradient of 99% A (water containing 0.1% acetic 
acid) and 1% B (acetonitrile containing 0.1% acetic acid) followed by linear increase to 90% B over 30 
min. The elution was continued at 90% B for 3 min and then B was decreased to 1% over next 8 min. A 
flow rate of 0.35 mL/min was used and the metabolites were detected at 254 nm. Mass spectra were 
obtained using electrospray ionization in the positive ion mode. Panel A: HPLC trace of the anaerobic 
reaction mixture with xanthine (1.6 mM) monitoring absorbance at 254 nm. Panel B: HPLC of the 
anaerobic reaction mixture with xanthine (2.4 mM) monitoring absorbance at 254 nm. Panel C: HPLC trace 
of the anaerobic reaction mixture with xanthine (4.0 mM) monitoring absorbance at 254 nm. Panel D: 
HPLC trace of the anaerobic reaction mixture with xanthine (6.4 mM) monitoring absorbance at 254 nm. 
Panel E: LC/MS spectrum of product eluting at 3.08 min in panels A and B. Panel F: LC/MS spectrum of 
the product eluting at 4.50 min in panels A, B, C and D. Panel G: LC/MS spectrum for of the product 
eluting at 14.60 min in panel A. Panel H: LC/MS spectrum for of the product eluting at 16.40 min in panels 
A, B, and C. Panel I: LC/MS spectrum for of the product eluting at 19.10 min in panels A, B, C and D. 
Panel J: LC/MS spectrum for of the product eluting at 24.50 min in panels A, B, C and D. 
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Figure 3.3. LC/MS analysis of authentic compounds. The compounds were dissolved in methanol. The 
mixture was eluted with a gradient of 99% A (water containing 0.1% acetic acid) and 1% B (acetonitrile 
containing 0.1% acetic acid) followed by linear increase to 90% B over 30 min. The elution was continued 
at 90% B for 3 min and then B was decreased to 1% over next 8 min. A flow rate of 0.35 mL/min was used 
and the metabolites were detected at 254 nm. Mass spectra were obtained using electrospray ionization in 
the positive ion mode. Panel A: HPLC trace of 50 monitoring absorbance at 254 nm. Panel B: LC/MS 
spectrum of 50. Panel C: HPLC trace of 43 monitoring at 254 nm. Panel D: LC/MS spectrum of 43 eluting 
at 4.50 min. Panel E: HPLC trace of 51 monitoring at 254 nm. Panel F: LC/MS spectrum of 51eluting at 
14.60 min.  Panel G: HPLC trace of 44 monitoring at 254 nm. Panel H: LC/MS spectrum of 44 eluting at 
15.10 min. Panel I: HPLC trace of 45 monitoring at 254 nm. Panel J: LC/MS spectrum of 45. Panel K: 
HPLC trace of 52 monitoring at 254 nm. Panel K: LC/MS spectrum of 52.   
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3.4 LC/MS analysis of the reaction mixtures generated by aerobic metabolism of 42 
by xanthine/xanthine oxidase 
Starting compound 42 is remaining in the mixture while 51 and 45 appeared as 
new products under aerobic conditions (Scheme 3.4). None of the compounds are 
fluorescent.  
 
 
 
 
 
Figure 3.4 LC/MS analysis of the reaction mixture generated by aerobic metabolism of 42. Compound 42 
(0.8 mM) xanthine oxidase (2.4 U/mL) and xanthine (6.4 mM) were mixed and the reaction was carried out 
as described in the experimental section. The reaction was dried and products dissolved in methanol.  The 
mixture was eluted with a gradient of 99% A (water containing 0.1% acetic acid) and 1% B (acetonitrile 
containing 0.1% acetic acid) followed by linear increase to 90% B over 30 min.  The elution was continued 
at 90% B for 3 min and then B was decreased to 1% over next 8 min.  A flow rate of 0.35 mL/min was used 
and the metabolites were detected at 254 nm.  Mass spectra were obtained using electrospray ionization in 
the positive ion mode.  Panel A: HPLC of the aerobic reaction mixture monitoring absorbance at 254 nm.  
Panel B:  LC/MS spectrum of the product eluting at 14.60 min.  Panel C: LC/MS spectrum of the product 
eluting at 17.10 min. Panel D: LC/MS spectrum for of the product eluting at 19.10 min. 
 
3.5 Xanthine oxidase oxidizes aryl carbon, bonded to heteroatom of 42 to produce 6-
nitroquinolone 51 
 The compound 51 (Figure 3.3, E), was synthesized using xanthine oxidase and 42 
as the starting material. There is evidence for oxidation of aromatic carbon, adjacent to 
nitrogen by enzyme xanthine oxidase.22 It was clear from the metabolic results of aerobic 
reaction of 42 by xanthine oxidase that xanthine oxidase does oxidation chemistry on 42, 
as a substrate when reduction of 42 is diminished in the presence of oxygen (Figure 3.4, 
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A). Moreover, at lower concentration of xanthine, under hypoxia 51 was produced as a 
main metabolite.  
We speculated that xanthine oxidase should be able to convert 42 to 51 under 
aerobic conditions and xanthine is not required for the oxidation process. When 42 stirred 
with xanthine oxidase in aqueous media, 51 was obtained in milligram amounts (Scheme 
3.5). 
 
 
 
Scheme 3.5. Enzymatic generation of 51 by 42 using xanthine oxidase 
Chemical characterization of 51 was conducted by NMR, HRMS and 
crystallography analysis (Figure 3.5 and experimental). Analysis of the 1H-NMR 
spectrum of 51 clearly shows the absence of the resonance for the proton adjacent to the 
nitrogen of the heterocyclic quinoline ring and a new resonance is seen on 13C spectrum 
at 165 ppm diagnostic for the carbonyl carbon of the quinolone system. 
 
 
 
 
 
 
 
Figure 3.5. ORTEP diagram of 51 
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When enzymatically synthesized 51 was analyzed on LC/MS (Figure 3.3, E and 
F), retention time and m/z matched with that which eluted with anaerobic and aerobic 
reactions (Figures 3.2, A and G, 3.3, E and F and 3.4, A and B).  
3.6 Hypoxia-selective conversion of hydroxylamine 50 to amino 43 
It is well established that enzymatic reduction of nitroaroamtics proceeds via 
intermediates nitroso and hydroxylamine to produce amine product.7a-c, 10, 23 The final 
reduction step from intermediate hydroxylamine to amine is not well studied in the 
current literature.24 The final reduction step of the reduction profile of 42 is studied using 
50 and the reduction of 50 is tested by xanthine and xanthine oxidase system under 
aerobic and anaerobic conditions. Characterization of enzyme mediated reduction of 
aromatic hydroxylamine to amine has not been reported (Scheme 3.6).  
 
 
 
 
Scheme 3.6 Enzymatic generation of 43 by xanthine and xanthine oxidase  
 
Hydroxylamine 50 has been chemically synthesized using hydrazine hydrate in 
the presence of Raney nickel and characterized using NMR, HRMS and crystallographic 
methods. The LC/MS characterization of 50 shows spontaneous formation of 49 and 45 
(Figure 3.3, panels A and B). The hypoxic incubation of 50 with xanthine oxidase and 
xanthine shows fluorescence growth at 530 nm and the fluorescence increases with 
xanthine concentration (Figure 3.6 A).  
70 
 
 
 
 
 
 
 
 
Figure 3.6. Enzymatic conversion of 50 to fluorescent 43 under hypoxic conditions. A. Fluorescence 
emission at 530 nm (λex 340 nm).  Each set of assays depicted in the bar graph consists of (from left to 
right): a control sample of compound 50 alone (0.8 mM) , a control reaction composed of xanthine 
oxidase (2.4 U/mL) and xanthine (2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) under aerobic , a control 
reaction composed of xanthine oxidase (2.4 U/mL) and xanthine (2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) 
under anaerobic conditions , a control reaction composed of xanthine oxidase (2.4 U/mL), xanthine (2.4 
mM, 3.2 mM, 4.0 mM and 6.4 mM) and the non-fluorescent electron acceptor, 1,2,4-benzotriazine 1,4-
dioxide, (6.4 mM) under aerobic conditions , a control reaction composed of xanthine oxidase (2.4 
U/mL), xanthine (2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) and the non-fluorescent electron acceptor, 1,2,4-
benzotriazine 1,4-dioxide, (6.4 mM) under anaerobic conditions , a reaction composed of xanthine 
oxidase (2.4 U/mL), xanthine (2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) and 50 under aerobic conditions , 
a reaction composed of xanthine oxidase (2.4 U/mL), xanthine (2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) 
and 50  under anaerobic conditions .  Reactions were incubated for 18 h in sodium phosphate buffer at 
(12 mM, pH 7.4) at 24 ˚C, diluted with aerobic sodium phosphate buffer (12 mM, pH 7.4), and the 
fluorescence was measured (λex 340 nm, λem 530 nm).  B. Fluorescence spectra of aerobic and anaerobic 
reaction mixtures containing 50 (0.8 mM), xanthine oxidase (2.4 U/mL), and xanthine (3.2 mM). 
 
 
In the aerobic reaction, fluorescence growth is not detected (Figure 3.10 panel F). 
The shape of the fluorescence curve of the anaerobic reaction is similar to 43 in solution 
(Figure 3.6 B). The LC/MS analysis of anaerobic reaction shows the presence of 43 and 
45. The evidence shows the oxygen sensitivity of reduction of 50 by xanthine and 
xanthine oxidase, to form 43 (Figure 3.7). 
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Figure 3.7. LC/MS analysis of the reaction mixture generated by anaerobic metabolism of 50. Compound 
50 (0.8 mM),xanthine oxidase (2.4 U/mL) and xanthine (6.4 mM) were mixed and the reaction was carried 
out as described in the experimental section. The reaction was dried and products dissolved in methanol. 
The mixture was eluted with a gradient of 99% A (water containing 0.1% acetic acid) and 1% B 
(acetonitrile containing 0.1% acetic acid) followed by linear increase to 90% B over 30 min. The elution 
was continued at 90% B for 3 min and then B was decreased to 1% over next 8 min. A flow rate of 0.35 
mL/min was used and the metabolites were detected at 254 nm. Mass spectra were obtained using 
electrospray ionization in the positive ion mode. Panel A: HPLC trace of the anaerobic reaction mixture 
monitoring absorbance at 254 nm. Panel B: LC/MS spectrum of the product eluting at 4.70 min.  Panel C:  
LC/MS spectrum of the product eluting at 19.20 min. 
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3.7 Hypoxia-selective conversion of 6-nitroquinolone 51 to 6-aminoquinolone 54 
 
 
 
Scheme 3.7. Enzymatic generation of 54 from 51 by xanthine and xanthine oxidase is hypoxia selective 
 
We speculated that the 6-aminoquinolone 54 may be fluorescent. The compound 
54 was chemically synthesized by reducing 51 on palladium/charcoal hydrogenation to 
obtain the fluorescent spectrum (Figure 3.10 panel B). Then, hypoxia selective reduction 
of 51 by xanthine and xanthine oxidase system is tested. The anaerobic reaction produced 
expected fluorescence of 54 (Scheme 3.7). A Sixteen fold increase of fluorescence is 
obtained against the aerobic reaction (Figure 3.8).  
 
 
 
 
 
 
 
 
Figure 3.8. Enzymatic conversions of 51 to 54 under hypoxic conditions. A. Fluorescence emission at 485 
nm (λex 390 nm) for 51 (0.8 mM) + xanthine oxidase (2.4 U/mL) and xanthine (3.2 mM) under aerobic 
conditions, 51 (0.8 mM) + xanthine oxidase (2.4 U/mL) and xanthine (3.2 mM) under anaerobic conditions, 
Reactions were incubated for 18 h in sodium phosphate buffer at (12 mM, pH 7.4) at 24 ˚C, then diluted 
with aerobic sodium phosphate buffer (12 mM, pH 7.4) and the fluorescence measured (λex 390 nm, λem 
485 nm). B. Fluorescence spectra (in sodium phosphate buffer, 10 mM, pH 7.4) of the reaction mixture 
generated in the aerobic metabolism of 51 by xanthine oxidase (2.4 U/mL) and xanthine (3.2 mM) (pink, 
λem 485 nm) and fluorescence spectrum (in sodium phosphate buffer, 10 mM, pH 7.4) of the reaction 
mixture generated in the aerobic metabolism of 51 by xanthine oxidase (2.4 U/mL) and xanthine (3.2 mM) 
(blue) λem 485 nm. 
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3.8 Enzymatic conversion of 42 to 6-nitroquinolone 51 followed by hypoxia-selective 
conversion to 6-aminoquinolone 54 
  LC/MS analysis of anaerobic and aerobic metabolism of 42 reveals that under low 
concentrations of xanthine, 42 was oxidized to form 51 and that oxidation can dominate 
over reduction of nitro under low oxygen levels. Upon forming 51, xanthine oxidase can 
perform nitro reduction on 51, under hypoxia to produce 54 in the same reaction mixture 
(Scheme 3.8).  
 
 
 
 
Scheme 3.8 Enzymatic generation of 51 from 42 and production of 54 from 51  
 
  In the assay we used 0.5 molar equivalent of xanthine, 0.4 mM, with 42 and 
xanthine oxidase and carried out the normal enzymatic reactions under anaerobic and 
aerobic conditions. In the fluorescence assays a ten-fold increase of fluorescence was 
obtained against the aerobic reaction mixture (Figure 3.9).  
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Figure 3.9 Enzymatic conversion of 42 to 51 and reduction to 54 in hypoxia. A. Fluorescence emission at 
485 nm (λex 390 nm) for 1 (0.8 mM) + xanthine oxidase (2.4 U/mL) and xanthine (0.4 mM) under aerobic 
conditions.Compound  1 (0.8 mM) + xanthine oxidase (2.4 U/mL) and xanthine (0.4 mM) were incubated 
for 18 h in sodium phosphate buffer at (12 mM, pH 7.4) at 24 ˚C under hypoxia, then diluted with aerobic 
sodium phosphate buffer (12 mM, pH 7.4) and the fluorescence measured (λex 390 nm, λem 485 nm). B. 
Fluorescence spectra (in sodium phosphate buffer, 10 mM, pH 7.4) of the reaction mixtures generated in 
the anaerobic(red) and aerobic(blue) metabolism of 42 by xanthine oxidase (2.4 U/mL) and xanthine (0.4 
mM) (λem at 485 nm)  
 
3.9 Conclusions 
  In the current work, we provide evidence for the hypoxia-selective conversion of 
6-nitroquinoline 42 to 6-aminoquinoline 43, by xanthine/xanthine oxidase enzyme 
system. The reduction steps are consecutive one electron additions, as seen in scheme 
3.1. In addition, condensation occurs between 50 and 49 to produce 45. The chemical 
synthesis and complete characterization of 50 facilitates the analysis of the oxygen 
sensitivity of final reduction step. Fluorescent and LC/MS analysis of reduction of 50 in 
hypoxia, by xanthine and xanthine oxidase show the presence of fluorescent 43. This 
finding is important and striking because the existing evidence in the literature discusses 
only the oxygen sensitivity of the first reduction step of nitro compounds.7d, 10, 25 The 
evidence we provide supports the existence of multiple oxygen sensitive reduction steps 
over the enzymatic reduction of nitro aromatic compound. In an early work, related to the 
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reduction of 42 by CYP450R15, together with current xanthine and xanthine oxidase-
mediated reduction of 42 in hypoxia shows different product profile and metabolism that 
may occur on a single nitro compound. The comparison reveals that the inability of 
CYP450R to reduce intermediate 50, under the conditions we applied, leaving them to 
condense to form byproducts.  
  We observed the oxidation of 42 to 51, conducted by xanthine oxidase (51, 
Scheme 3.4). The ability of xanthine oxidase to oxidize aromatic carbon atoms next to 
nitrogen is well documented.22b, 22d The oxidizing capability of xanthine oxidase is 
responsible for the transformation of 42 to 51. The aerobic assays show the oxidation 
product 51 as a major product. Upon reduction 51 produces fluorescent 54, which emits 
at 490 nm (data not shown) under assay conditions. In assays, when xanthine 
concentration is increased the yield of 51 decreases. Hence, it can be concluded that 
under anaerobic conditions xanthine/xanthine oxidase system efficiently reduces 42. The 
oxidizing ability of xanthine oxidase slows when conditions for reduction is favored.  
 Reduction of 51, in a separate experiment by xanthine/xanthine oxidase system, 
under hypoxia produces fluorescence at 485 nm. The emission parameters of 54 match 
with the fluorescence obtained from the anaerobic metabolism of 51 (data not shown). 
The fluorescent enhancement obtained with 51 grants future experiments on 51 as a 
potential fluorescent probe to detect hypoxia. 
 Finally, the work we presented shows the ability of 42 to be used as a fluorescent 
probe that can be activated by one electron reductases, under hypoxia. Chemical 
characterization of metabolites, produced from enzymatic reduction of nitroaromatic 
compounds is essential to understand the complexity of nitroaromatic reduction.  
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3.10 Experimental 
Materials and methods.  Chemicals were purchased from following sources: Sodium 
phosphate, glucose, NADPH, cytochrome p450 reductase, DMF, Raney nickel slurry in 
water, silica gel plates for thin layer chromatography and silica gel (0.04-0.063 mm pore 
size) for column chromatography were obtained from Sigma Aldrich (St. Louis, MO); 6-
aminoquinoline, 6-nitroquinoline, and hydrazine hydrate from Alfa-Aesar (Ward Hill, 
MA). deuterated NMR solvents were from Cambridge Isotope Laboratories (Andover, 
MA); ethyl acetate, dichloromethane, methanol, hexane, ethanol, HPLC water and HPLC 
acetonitrile from Fischer; The compound 1,2,4-benzotriazine-1,4-di-N-oxide was made 
following literature methods.1 High resolution mass spectrometry (HRMS) analyses were 
performed at the mass spectroscopy facility of the University of Illinois Champaign-
Urbana and low resolution mass spectroscopic analyses were carried out at the University 
of Missouri-Columbia. 1H and 13C NMR experiments and were done on a Bruker Avance 
DRX300 with 5 mm broadband probe and Bruker Avance DRX500 with CPTCI probe 
using deuterated NMR solvents methanol (CD3OD) and chloroform(CDCl3) at the 
University of Missouri-Columbia. The reference peaks were set to 3.31 ppm and 49.00 
ppm for deuterated methanol and 7.26 ppm and 77.00 ppm for deuterated chloroform 
from tetramethylsilane for the 1H and 13C spectra respectively. The fluorescence spectra 
were obtained on a Varian Cary Eclipse Fluorescence Spectrophotometer equipped with 
xenon flash lamp with instrumental slit width settings at 10 nm employing a 10 mm path 
length quartz cuvette. 
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Figure 3.10. Fluorescence spectra of control reactions. A: Fluorescence spectrum of 50  (0.03 mM, λex 
340 nm, in sodium phosphate buffer, 10 mM, pH 7.4). B: Fluorescence spectrum of 54  (0.003 mM, λex 
390 nm, in sodium phosphate buffer, 10 mM, pH 7.4). C: Fluorescence spectra (λex 340 nm, in sodium 
phosphate buffer, 10 mM, pH 7.4) of control reactions composed of xanthine oxidase (2.4 U/mL), xanthine 
(2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) and a non-fluorescent electron acceptor 1,2,4-benzotriazine 1,4-
dioxide (6.4 mM) under aerobic conditions ( referred to brown bar in figure 3.1, ), D: Fluorescence 
spectra of control reactions composed of xanthine oxidase (2.4 U/mL), xanthine (2.4 mM, 3.2 mM, 4.0 mM 
and 6.4 mM) and a non-fluorescent electron acceptor 1,2,4-benzotriazine 1,4-dioxide (6.4 mM) under 
anaerobic conditions (referred to green bar in figure 3.1 A, ) E: Fluorescence spectra (λex 340 nm, in 
sodium phosphate buffer, 10 mM, pH 7.4) of reactions composed of xanthine oxidase (2.4 U/mL), xanthine 
(2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) and 42 under aerobic conditions ( blue bar in figure 3.1 A, ), F: 
Fluorescence spectra (λex 340 nm, in sodium phosphate buffer, 10 mM, pH 7.4) of reactions composed of 
xanthine oxidase (2.4 U/mL), xanthine (2.4 mM, 3.2 mM, 4.0 mM and 6.4 mM) and 50 under aerobic 
conditions. 
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Synthesis of 6-hydroxylaminoquinoline 50:1 
 
6-nitroquinoline (0.5 g, 2.87 mmol) 42 was stirred in 20 mL of EtOH/CH2Cl2 
(1:1) at 00C and 0.5 mL of was Raney nickel slurry (active catalyst in water-sigma 
221678) was added. Then, 10 molar eq. of hydrazine hydrate was added drop wise and 
stirred for 1 hour while purging nitrogen gas. The solid was filtered and the organic 
mixture was dried using brine and sodium sulfate. The compound 50 was separated by 
column chromatography using EtOAc and MeOH/ CH2Cl2 solvents. To obtain crystals, 
the pure product was dissolved in warm EtOAc and was cooled rapidly to isolate yellow 
crystals. 1H – NMR (CD3OD, 300 MHz,): δ 8.53 (d, J = 5.0 Hz, 1H), 8.07 (d, J = 8.0 Hz, 
1H), 7.82 (m, 1H), 7.33 (m, 3H). 13C NMR (CD3OD, 300 MHz): δ 151.40, 147.64, 
144.76, 136.72, 131.05, 129.15, 122.54, 121.01, 107.68. HRMS (ESI, M+H+) m/z calcd 
for C9H9N2O 160.0715, found 160.0707 
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Synthesis of 1,2-di(quinolin-6-yl)diazene oxide 45 
 
 
We employed a variation on the literature procedure of Boge et al.2 To a solution 
of compound 42 (0.5 g, 2.87 mmol) in a mixture of EtOH:CH2Cl2 (1:1, 20 mL) at 0 ˚C in 
an ice/salt bath was added Raney nickel slurry (0.5 mL, active catalyst in water, Sigma-
Aldrich cat. number 221678).  To this mixture, hydrazine hydrate (1.5 mL, 30 mmol) 
portions were added over the course of 3 h with stirring until 42 was consumed (TLC) 
and the resulting mixture stirred overnight. The solid was removed by filtration and the 
resulting solution dried by extraction with brine and then over sodium sulfate. The 
compound was purified by column chromatography on silica gel eluted with ethyl acetate 
in the first column separation and the second column chromatography separation on silica 
gel was done with MeOH:CH2Cl2 (99:1) to obtain the product, a yellow solid, in pure 
form (100 mg, Rf value = 0.25 in 4% MeOH in CH2Cl2) 1H NMR (CDCl3, 300 MHz): δ 
ppm 9.14 (d, J = 2.5 Hz, 1H), δ 9.00 (dd, J = 4.5 Hz, J = 1.5 Hz, 1H), δ 8.93 (dd, , J = 4.5 
Hz, J = 1.5 Hz, 1H), δ 8.82 (d, J = 2.5 Hz, 1H), δ 8.67 (d, J = 9.0 Hz, 1H), δ 8.31 (dd, J = 
9.0 Hz, J = 1.5 Hz, 1H), δ 8.21 (m, 4H), δ 7.49 (dd, J = 8.5 Hz,  J = 4.5 Hz, 1H), 7.42 (dd, 
J = 8.5 Hz, J = 4.5 Hz, 1H), 1.23 grease. 13C NMR (CDCl3, 75.5 MHz): δ 152.86, 151.97, 
149.64, 148.72, 146.01, 141.93, 137.88, 137.76, 130.95, 130.32, 129.32, 128.46, 127.73, 
123.76, 123.40, 122.68, 122.64, 122.09; HRMS (ESI, [M+H]+) m/z calcd for C18H13N4O 
301.1089, found 301.1080. 2Boge, N.; Kruger, S.; Schroder, M.; Meier, C.; Synthesis 
2007, 24, 3907-3914. 
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Synthesis of 52 
 
 
 
 
The compound 44 (0.01 g, 0.0335 mmol) in 70 % EtOH:water (2.5 mL) was 
added with sodium dithionite( 0.012 g, 0.07 mmol) and was refluxed for 30 min. The 
reaction mixture was filtered and dried with brine and magnesium sulfate. The crude 
material was separated by silica gel column chromatography using EtOAc to obtain the 
product 52.   1H – NMR (CDCl3, 500 MHz): δ 9.11 (d, J = 4.5 Hz, 2H), 9.01 (d, J = 8.0 
Hz, 2H), 8.85 (d, J = 9.0 Hz, 2H), 8.46 (d, J = 9.0 Hz, 2H), 7.43 (dd, J = 8.0 Hz, J = 4.5 
Hz, 2H). 13C-NMR (CDCl3, 125.77 MHz): δ 152.66, 149.77, 146.06, 136.07, 132.75, 
130.81, 123.18, 120.14, 119.28. HRMS (ESI, M+H+) m/z calcd C18H11N4 calculated mass 
283.0984; actual mass 283.0982 
Synthesis of 6-nitroquinolone 51 
 
 
6-nitroquinoline (250 mg, 1.315 mmol) 42 was dissolved in warm DMF (1 mL) 
and squirted into warm water (300 mL) while stirring vigorously. Then warm sodium 
phosphate (500 mM, 100 mL, pH 7.4) was added while stirring. Then xanthine oxidase 
(100 µL, 0.005 U/mL) was added in 12-hour intervals for 3 days. The organic material 
was extracted to EtOAc and dried using brine and sodium sulfate. The product was 
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separated by column chromatography using hexane and ethyl acetate to obtain 4 mg of 
product 51. The crystals were obtained by dissolving the pure compound in minimum 
amount of warm ethyl acetate and slow evaporation for 3 days.  
1H – NMR (CD3OD, 500 MHz): δ 8.64 (d, J = 2.5 Hz, 1H), 8.36 (dd, J = 9.0 Hz, J = 2.5 
Hz, 1H), 8.09 (d, J = 9.0 Hz, 1H), 7.46 (d, J = 9.0 Hz, 1H), 6.73 (d, J = 9.0 Hz, 1H); 13C-
NMR (CD3OD, 125.77 MHz) δ 165.01, 144.11, 144.05, 142.25, 126.28, 125.37, 124.33, 
120.63, 117.44 ; HRMS (ESI, M+H+) m/z calcd C9H7N2O3 calculated mass 191.0457; 
actual mass 191.0456  
Synthesis of 6-aminoquinolone 54 
 
 
6-nitroquinolone (10 mg, 0.05 mmol) 51 was dissolved in MeOH (10 mL) and 
was added with Pd on activated carbon (0.5 mg). The hydrogen gas was bubbled for 10 
mins. The reaction mixture was filtered and organic material was dried using brine and 
sodium sulfate. The product was separated by silica gel column chromatography using 
1% methanol:ethyl acetate as the mobile solvent system to obtain 2 mg of product 54. 1H 
– NMR (CD3OD, 500 MHz,): δ 7.80 (dd, J = 9.0 Hz, J = 3.3 Hz 1H), 7.16 (d, J = 9.0 Hz, 
1H), 7.02 (d, J = 9.0 Hz, 1H), 6.92 (t, J = 3.3, J = 3.1 Hz, 1H), 6.54 (dd, J = 9.0 Hz, 3.1 
Hz, 1H), 1.28 grease. 13C-NMR (CD3OD, 125.77 MHz): δ 164.59, 144.90, 142.29, 
132.46, 122.52, 122.05, 121.45, 117.50, 112.34. HRMS (ESI, M+H+) m/z calcd C9H9N2O 
calculated mass 161.0715; actual mass 161.0714 
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Procedure for hypoxic metabolism.  
In a typical enzymatic reaction, 42 ( 4 µL from 50 mM in DMF, final 
concentration 0.8 mM), 50, 51 or non-fluorescent electron acceptor (24 µL from 50 mM 
in 15 % DMF water, final concentration 6.4 mM), was added to xanthine in water(20-160 
µL of 10 mM, final concentration 0.8 mM-6.4 mM. Then, xanthine oxidase (20 µL from 
20 U/mL, final concentration 2.4 U/mL), sodium phosphate buffer (6 µL from 50 mM, 
final concentration 12 mM, pH 7.4) and HPLC water were added to xanthine-42 solution 
to obtain the final solution (0.25mL, less than 2% DMF) at room temperature (240C). In 
anaerobic reactions, all reagents except xanthine oxidase were de-gassed in glass tubes by 
three freeze pump thaw cycles. The glass tubes were broke open inside an argon-purged 
glove bag and bubbled with argon for five minutes. All reagents were mixed inside the 
glove bag. Upon mixing, the containers were wrapped with aluminum foil to prevent 
exposure to light.  
Procedure for Fluorescence experiment 
Upon completion of incubation reaction solution was diluted up to 1 mL with 
sodium phosphate buffer (50 mM, pH 7.4) in HPLC water and then was added to the 
cuvette. In anaerobic experiments, upon completion the reaction mixtures were taken out 
of glove bag and kept 1 h under atmospheric conditions prior to the dilutions.  
Procedure for LC/MS analysis.  In vitro enzymatic metabolism of 42 or 50 was carried 
out as described above and the resulting products were extracted into ethyl acetate and 
dried using brine followed by roto vap evaporation of ethyl acetate.  The solid was re-
dissolved in methanol and analyzed by LC/MS in the positive ion mode.  Separation of 
metabolites was carried using a C18 reverse phase Phenomenex Luna column (5 µm 
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particle size, 100 A0 pore size, 150 mm length, 2.00 mm i.d.) and a ThermoSeparations 
liquid chromatograph (TSP4000) and the metabolites were detected by their UV-
absorbance at 254 nm.  The elution started with a gradient of A, 99% HPLC water (0.1% 
acetic acid) and B acetonitrile (0.1% acetic acid) followed by a linear increase to 90 % B 
over the course of 30 min.  The elution was continued at 90% B for 3 min and decreased 
to 1% over the next 8 min.  A flow rate of 0.35 mL/min was used.  The LC/ESI-MS 
analyses were carried out in the positive ion mode on a Finnigan TSQ 7000 triple 
quadrupole instrument using a 250 kV needle voltage and at a capillary temperature of 
250 ˚C. 
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1H – NMR of 50 (300 MHz, MeOD)  
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13C NMR of 50 (MeOD, 125.77 MHz) 
 
 
 
86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR of 45 (CDCl3, 300 MHz) 
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13C NMR of 45 (CDCl3, 75.5 MHz) 
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1H NMR of 52 (CDCl3, 500 MHz) 
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13C NMR of 52 (CDCl3, 125.77 MHz) 
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1H – NMR of 51 (500 MHz, MeOD)  
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13C NMR of 51 (MeOD, 125.77 MHz) 
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1H NMR of 54 (CDCl3, 500 MHz) 
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13C NMR of 54 (CDCl3, 125.77 MHz) 
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Chapter 4  
Mechanistic analysis related to the oxidative DNA Damage caused by 
1,2,4-benzotraizine-di-oxides, TPZ and analogs of TPZ 
 
4.1 Introduction   
 
Tirapazamine, 33, (TPZ), 3-amino-1,2,4-benzotriazine 1,4-dioxide is currently in 
phase І, ІІ and ІІІ clinical trials for tumor therapy.1 TPZ emerged as the lead compound 
among di N-oxide bioreductive drugs.2 TPZ causes cytotoxicity to cell, as found in low 
oxygenated regions (hypoxic) in solid tumors.3 It is believed that the anti-cancer activity 
caused by TPZ originates from its ability to cleave DNA under hypoxia.4 The DNA 
damage, caused to tumor cells by TPZ arises from the drug radical anion, which is 
produced by the reduction of TPZ by cellular reductases under low oxygen levels.5 The 
enzymatic reduction of TPZ is an oxygen sensitive reaction.3a, 6 The oxygen sensitivity is 
due to the oxidation of TPZ radical anion 37, which is formed by the main forward 
reduction step, back to the parent TPZ.7 Molecular oxygen forms superoxide radical in 
the back oxidation step.8 The oxidative stress arises due to the superoxide radical 
formation, in normal oxygenated conditions, but this process is reduced by cellular 
defense system against reactive oxygen species, which is a collection of enzymes such as 
glutathione peroxidase, peroxiredoxins, catalase, and superoxide dismutase.9 In hypoxia 
TPZ radical anion 37 gets protonated to a drug radical 34.10 DNA is the prime target of 
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the oxidizing species generated following the reduction of TPZ.11 The neutral drug 
radical 34 generates a DNA damaging radical species before ultimately producing the 
major metabolite 35 (Scheme 4.1).12 
 
 
 
 
 
 
Scheme 4.1. Enzymatic reduction of 33 produces DNA damaging radicals and oxidative stress 
The oxidative damage to DNA, caused by TPZ is characterized as proton 
abstraction from deoxyribose sugar backbone and DNA bases.5b The oxidative damage to 
DNA leads to DNA strand breaks.13 The chemical nature of the DNA damaging species 
that is emitted during the oxygen sensitive enzymatic reduction of TPZ is not completely 
characterized.10, 14  
4.2 Mechanistic evidence for the oxidizing radical formation by TPZ 
 Research carried out by our group suggests that the activated TPZ produces a 
radical anion 37 and under low oxygen levels 37 undergoes protonation to produce 34, 
followed by a homolytic bond scission on 34 releases hydroxyl radical and produces 1-N-
oxide metabolite 35.4a, 14c, 15 Similar homolytic fragmentation is proposed on Barton’s N-
hydroxypyridinethione esters in literature.16 Another report on N-(alkoxy) pyridinium 
salts discusses homolytic fragmentation induced by photo-induction.17 Moreover, radical 
scavenging experiments and DNA cleavage pattern studies suggest that homolytic 
fragmentation of di-N-oxides such as 34 to produce hydroxyl radical is chemically 
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plausible.4a, 14c Another hypothesis proposed by Denny and co-workers, suggests that 34 
undergoes dehydration to form benzotriazinyl radical 38 and they provide evidence for 38 
as the species that is responsible for the DNA damage caused by TPZ.10, 14a, b 
Intermediate 34 is, generated radiolytically and has been tested for DNA damage.18 
Similar organic radical formation is reported when hydroxyl radicals are generated by 
pulse radiolysis in the presence of toluene to produce benzyl radicals.19 
 
 
 
 
 
 
Scheme 4.2. Different mechanisms are proposed to explain enzymatic metabolism of 33  
 We feel that mechanistic investigation of bio-reductive activation of TPZ under 
low oxygen concentrations may provide a better understanding on the chemical structure 
of the DNA damaging species and could be important in designing novel TPZ analogs. 
4.3 Hypothesis and design of experiments 
 The benzotriazine 1,4-dioxide analog (desH) 55 may be used to analyze the 
dehydration mechanism of benzotriazine di-oxides. Metabolic studies of 55 when 55 was 
enzymatically reduced, in hypoxia may produce 59 as the major metabolite.20 The 
enzymatic metabolism of 55 might be similar to that of 1,2,4-benzotriazine 1,4-dioxide 
drug class; the major metabolite formed is 1,2,4-benzotriazine 1-mono-oxide.14c The 
reduction profile of 55 mirrors the metabolism of 1,2,4-benzotriazine 1,4-dioxide 
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(Scheme 4.3).20 In the enzyme mediated, one electron reduction of 55, radical anion 56, is 
produced and under normal oxygen concentration, 56 can be oxidized back to 55.20 
Under hypoxia 56 gets protonated to form the drug radical 57, which produces the DNA 
damaging species and the major metabolite 59.20b The dehydration mechanism produces 
radical 58 by eliminating a water molecule. The radical 58 may abstract a proton from an 
organic substrate to undergo re-aromatization to form 59 (lower arm). Alternatively, 
hydroxyl radical mechanism performs homolytic fragmentation on 57 to produce 
hydroxyl radical and the major metabolite 59.  
 
 
 
 
 
 
Scheme 4.3. Enzymatic reduction of 55 under low oxygen concentrations forms major metabolite 59 
 In the design, we speculated that deuterated analog of 1,2,4-benzotriazine- 1,4-
dioxide 60 (desD) may offer a new approach to analyze the dehydration mechanism. 
When 1,2,4-benzotriazine- 1,4-dioxide 60 is reductively activated to radical anion 61, 
protonation occurs to form neutral radical 62. The homolytic fragmentation of 63 
produces hydroxyl radical and the major metabolite 63. When the dehydration 
mechanism occurs on 60, the neutral drug radical 62 converts to radical 58 and 58 may 
abstract a deuterium from an organic substrate to produce 63. Similarly, when 55 is 
reductively activated under hypoxia, in the presence of a deuterated organic substrate, the 
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dehydration mechanism might produce radical 58 and, upon deuterium abstraction major 
metabolite 63. Accordingly, the loss or incorporation of deuterium/hydrogen can be 
detected when the isotopic content of the major metabolite 1-oxide is analyzed using 
mass spectrometry (Scheme 4.4). 
 
 
 
 
 
 
 
Scheme 4.4. Isotopic content of major metabolite of 55/60 determines mechanism 
4.4 Examine the dehydration mechanism in relation to the release of oxidizing 
species from 1,2,4-benzotriazine-di-oxide  
 Various TPZ analogs such as 3-methyl-1,2,4-benzotriazine 1,4-dioxide (Me-TPZ) 
and 1,2,4-benzotriazine 1,4-dioxide, 55, have been used in cytotoxicity assays.21 The 
anti-cancer activity of these analogs is similar and comparable to that of TPZ. 
Structurally and functionally similar benzotriazine di-oxide analogs can be used as tools 
to study the chemical nature of DNA damaging species and mechanism for the formation 
of DNA damaging species.14b, c, 22 A study carried out by Raman Junnotula in our group 
used 3-methyl-1,2,4-benzotriazine 1,4-dioxide (MeTPZ) to investigate the formation of 
benzotriazinyl radical and explored the dehydration mechanism.20b The current chapter 
describes a similar related mechanistic study. In the beginning, compounds 55 and 60 are 
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synthesized. The metabolism and DNA damaging properties of 55 and 60 were compared 
against TPZ for their ability to cause DNA damage under reductive enzyme activated 
hypoxic conditions. 
  4.5 Chemical Synthesis of 1,2,4-benzotriazine-1,4-dioxide 
 The compound 1,2,4-benzotriazine 1,4-dioxide 55 was obtained by known 
methods using TPZ as the starting material in the preparation. Briefly, in an argon-purged 
glove bag two glass vials were added with TPZ in anhydrous DMF and tert-butyl nitrite 
in anhydrous DMF (argon was purged upon preparing stock solutions). Then, the tert-
butyl nitrite solution was heated to 650C, and to this TPZ in DMF was added slowly over 
10 min. Then the mixture was cooled to room temperature. The solution was removed 
from the glove bag, and DMF was removed using high vacuum. Brownish yellow crude 
material was used to perform column chromatography, followed by preparative thin layer 
chromatography separated product 55. The deuterated analog 60 was prepared using 
deuterated DMF as the solvent. Synthesis of 55 was followed exactly to prepare and 
separate 60. The compound 3-amino 1,2,4-benzotriazine 1-N oxide 35 was used as the 
starting material to prepare 1,2,4-benzotriazine 1-N oxides 59 and 63. Same procedure, 
which was followed to synthesize 55 was adopted in the preparation of 59.and 63, using 
deuterated DMF as the solvent.   
4.6  DNA-damaging properties of 1,2,4-benzotriazine-1,4-dioxide analogs and 
TPZ 
4.6.1  TPZ analogs perform concentration dependent DNA damage 
 Cytotoxicity caused by TPZ and 1,2,4-benzotriazine-1,4-dioxide 55 are similar.21a 
In TPZ, the cytotoxicity derives from its ability to initiate oxidative damage to cellular 
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DNA. In the current work, the damage to DNA caused by TPZ was analyzed using 
plasmid DNA damage based assays. In the plasmid DNA-based assay, the supercoiled 
form І DNA molecule converts to form ІІ when a hydrogen atom is abstracted from the 
sugar phosphate backbone. The DNA which is nicked will be converted to form ІІ and 
intact DNA, the form І, is detected and quantified on agarose gel-based method.23 Similar 
DNA-damaging study with 55 and 60 provides a comparative DNA damage study among 
TPZ drug class. In the anaerobic assays TPZ, 55 or 60 were activated using 
NADPH:cytochrome P450 reductase and upon activation the oxidative DNA damage 
would assume on plasmid DNA. Gel pictures obtained upon completion of assays, 
conducted using TPZ, 55 and 60 showed an increase in the amount of form ІІ DNA with 
the concentration of respective di- N-oxide (Figures 4.1, 4.2 and 4.3).  
  
 
 
Figure 4.1: Cleavage of supercoiled plasmid DNA by 33 (50-250 µM) in the presence of 
NADPH:cytochrome P450 reductase as an activating system. All reactions contained DNA (33 µg/mL, 
pGL-2 Basic), sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (2.5% v/v), catalase (100 µg/ mL), 
superoxide dismutase (10 µg/mL), and desferal (1 mM) and were incubated under anaerobic conditions at 
24 °C for 6 h, followed by agarose gel electrophoretic analysis. lane 1, 33 (50 µM) + NADPH (500 µM) + 
reductase (33 mU/mL) (S = 0.75 ± 0.04); lane 2, 33 (100 µM) + NADPH (500 µM) + reductase (33 
mU/mL) (S = 1.25 ± 0.14); lane 3, 33 (150 µM) + NADPH (500 µM) + reductase (33 mU/mL) (S = 1.74 ± 
0.21); lane 4, 33 (200 µM) + NADPH (500 µM) + reductase (33 mU/mL) (S = 2.58 ± 0.14); lane 5, 33 (250 
µM) + NADPH (500 µM) + reductase (33 mU/mL) (S = 3.53 ± 0.32).The value S represents the mean 
number of strand breaks per plasmid molecule and is calculated using the equation S = –ln fI, where fI is the 
fraction of plasmid present as form I.  
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Figure 4.2: Cleavage of supercoiled plasmid DNA by 55 (50-250 µM) in the presence of 
NADPH:cytochrome P450 reductase as an activating system. All reactions contained DNA (33 µg/mL, 
pGL-2 Basic), sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (2.5% v/v), catalase (100 µg/ mL), 
superoxide dismutase (10 µg/mL), and desferal (1 mM) and were incubated under anaerobic conditions  at 
24 °C for 6 h, followed by agarose gel electrophoretic analysis. lane 1, 55 (50 µM) + NADPH (500 µM) + 
reductase (33 mU/mL) (S = 0.77 ± 0.02); lane 2, 55 (100 µM) + NADPH (500 µM) + reductase (33 
mU/mL) (S = 1.10 ± 0.08); lane 3, 55 (150 µM) + NADPH (500 µM) + reductase (33 mU/mL) (S = 1.27 ± 
0.07); lane 4, 55 (200 µM) + NADPH (500 µM) + reductase (33 mU/mL) (S = 1.71 ± 0.17); lane 5, 55 (250 
µM) + NADPH (500 µM) + reductase (33 mU/mL) (S = 2.19 ± 0.20).The value S represents the mean 
number of strand breaks per plasmid molecule and is calculated using the equation S = –ln fI, where fI is the 
fraction of plasmid present as form I.24 
 
 
 
 
Figure 4.3: Cleavage of supercoiled plasmid DNA by 60 (50-250 µM) in the presence of 
NADPH:cytochrome P450 reductase as an activating system. All reactions contained DNA (33 µg/mL, 
pGL-2 Basic), sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (2.5% v/v), catalase (100 µg/ mL), 
superoxide dismutase (10 µg/mL), and desferal (1 mM) and were incubated under anaerobic conditions at 
24 °C for 6 h, followed by agarose gel electrophoretic analysis. lane 1, 60 (50 µM) + NADPH (500 µM) + 
reductase (33 mU/mL) (S = 0.66 ± 0.04); lane 2, 60 (100 µM) + NADPH (500 µM) + reductase (33 
mU/mL) (S = 0.87 ± 0.07); lane 3, 60 (150 µM) + NADPH (500 µM) + reductase (33 mU/mL) (S = 1.12 ± 
0.12); lane 4, 60 (200 µM) + NADPH (500 µM) + reductase (33 mU/mL) (S = 1.36 ± 0.03); lane 5, 60 (250 
µM) + NADPH (500 µM) + reductase (33 mU/mL) (S = 1.81 ± 0.22).The value S represents the mean 
number of strand breaks per plasmid molecule and is calculated using the equation S = –ln fI, where fI is the 
fraction of plasmid present as form I. 
  
 The amount of nicking can be represented as S values (S = –ln fI, where fI is the 
fraction of plasmid present as form I) of TPZ, 55 and 60. The S values of TPZ, 55 and 
60 show a positive correlation between DNA strand cleavage and respective drug 
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concentration. As the concentration of drug is increased, under identical enzyme 
mediated reductive activation, the DNA damage is increased (Figures 4.1, 4.2, 4.3 and 
4.4). This behavior is a reported trend among N-di-oxides when they are metabolized in 
the presence of plasmid DNA under reductively activated hypoxic conditions.25 In 
addition, control experiments were carried out without the activating enzyme, substrate or 
drugs to show that the observed DNA damage occurs solely due to the reductively 
activation of di-N-oxides. Reductive activation, under aerobic conditions, of TPZ, 55 or 
60 is unable to produce considerable DNA damage compared to anaerobic reactions 
(Table 1).  
4.6.2  DNA damage is decreased by radical scavengers 
 
 
 
 
 
 
 
 
Figure 4.4. Comparison of DNA cleavage by reductively activated 33, 55 and 60 under anaerobic 
conditions (black line-strand cleavage by 33, red line-55 and green line-60. Supercoiled plasmid DNA (33 
µg/mL, pGL-2 Basic) was incubated with drug (50-250 µM), NADPH (500 µM), cytochrome P450 
reductase (33 mU/mL), catalase (100 µg/mL), superoxide dismutase (10 µg/mL), sodium phosphate buffer 
(50 mM, pH 7.0), acetonitrile (0.5-2.5% v/v), and desferal (1 mM) under anaerobic conditions at room 
temperature for 6 h, followed by agarose gel electrophoretic analysis.  The values, S, derived from agarose 
gel data and represent the mean number of strand breaks per plasmid molecule and were calculated using 
the equation S = –ln fI, where fI is the fraction of plasmid present as form I.24 Background cleavage in the 
untreated plasmid was subtracted to allow direct comparison of DNA cleavage yields between different 
experiments. 
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Reaction % form II  S value 
DNA alone 17.4 0.19±0.07 
NADPH:cytochrome P450 
reductase/NADPH aerobic 14.3 0.15±0.06 
NADPH:cytochrome P450 reductase 17.3 0.19±0.02 
55 alone 16.5 0.18±0.03 
55+NADPH:cytochromeP450 
reductase/NADPH aerobic 17.0 0.18±0.03 
60 alone 29.3 0.38±0.70 
60+NADPH:cytochromeP450 
reductase/NADPH aerobic  25.8 0.29±0.74 
55 alone 16.5 0.18±0.03 
55+NADPH:cytochromeP450 
reductase/NADPH aerobic 17.0 0.18±0.03 
33 alone 11.6 0.19±0.01 
33+NADPH:cytochromeP450 
reductase/NADPH aerobic 20.7 0.23±0.08 
 
Table 4.1. Cleavage of plasmid DNA in control reactions 
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To test the chemical nature of the DNA damaging species, plasmid DNA based 
damaging assays were carried out in the presence of radical scavenging agents as a 
reagent in reaction solutions. The DNA damage caused by 33, under reductive enzyme 
activity in hypoxia, diminishes in the presence of radical scavenging agents such as 
methanol, ethanol, t-butanol, DMSO and mannitol. Analogous radical scavenging assays 
were carried out using 55 and 60. The agarose gels obtained from the radical scavenging 
assays of 55 and 60 are qualitatively and quantitatively comparable with those obtained 
with 33 (Figures 4.5, 4.6 and 4.7). The DNA damage caused by reductive activation of 
33, 55 and 60 under hypoxia has been decreased by the addition of radical scavengers. It 
is well established that the radical scavengers used in the current assay reacts with 
hydroxyl radicals. Hence, homolytic fragmentation mechanism, which is proposed to 
explain the formation of hydroxyl radical in the metabolism of 33, is also plausible to 
occur when 55 and 60 undergo reductive activation in our assay conditions  
 
 
 
 
 
 
 
Figure 4.5. Cleavage of supercoiled plasmid DNA by 33 (25 µM) in the presence of NADPH:cytochrome 
P450 reductase as an activating system is reduced by radical scavengers. All reactions contained DNA (33 
µg/mL, pGL-2 Basic), sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (2.5% v/v), catalase (100 µg/ 
mL), superoxide dismutase (10 µg/mL), and desferal (1 mM) and were incubated under anaerobic 
conditions at 24 °C for 4 h, followed by agarose gel electrophoretic analysis. Lane 1, 33 (50 µM) + 
NADPH (500 µM) + reductase (33 mU/mL) (S = 0.67 ± 0.09); lanes 2-6, 33  (50 µM) + NADPH (500 µM) 
+ reductase (33 mU/mL) + methanol (500 mM, lane 2) (S = 0.32 ± 0.01); ethanol (500 mM, lane 3) (S = 
0.35 ± 0.04); tert-butyl alcohol (500 mM, lane 4) (S = 0.32 ± 0.05); DMSO (500 mM, lane 5) (S = 0.35 ± 
0.06); mannitol (500 mM, lane 6) (S = 0.32 ± 0.05);. The value S represents the mean number of strand 
breaks per plasmid molecule and is calculated using the equation S = –ln fI, where fI is the fraction of 
plasmid present as form I. 
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Figure 4.6. Cleavage of supercoiled plasmid DNA by 55 (50 µM) in the presence of NADPH:cytochrome 
P450 reductase as an activating system is reduced by radical scavengers. All reactions contained DNA (33 
µg/mL, pGL-2 Basic), sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (2.5% v/v), catalase (100 µg/ 
mL), superoxide dismutase (10 µg/mL), and desferal (1 mM) and were incubated under anaerobic 
conditions at 24 °C for 4 h, followed by agarose gel electrophoretic analysis. Lane 1, 55 (50 µM) + 
NADPH (500 µM) + reductase (33 mU/mL) (S = 0.66 ± 0.13); lanes 2-6, 55 (50 µM) + NADPH (500 µM) 
+ reductase (33 mU/mL) + methanol (500 mM, lane 2) (S = 0.25 ± 0.08); ethanol (500 mM, lane 3) (S = 
0.29 ± 0.08); tert-butyl alcohol (500 mM, lane 4) (S = 0.27 ± 0.04); DMSO (500 mM, lane 5) (S = 0.30 ± 
0.04); mannitol (500 mM, lane 6) (S = 0.28 ± 0.07);. The value S represents the mean number of strand 
breaks per plasmid molecule and is calculated using the equation S = –ln fI, where fI is the fraction of 
plasmid present as form I. 
 
 
 
 
 
 
 
 
 
Figure 4.7. Cleavage of supercoiled plasmid DNA by 60 (50 µM) in the presence of NADPH:cytochrome 
P450 reductase as an activating system is reduced by radical scavengers. All reactions contained DNA (33 
µg/mL, pGL-2 Basic), sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (2.5% v/v), catalase (100 µg/ 
mL), superoxide dismutase (10 µg/mL), and desferal (1 mM) and were incubated under anaerobic 
conditions at 24 °C for 4 h, followed by agarose gel electrophoretic analysis. Lane 1, 60 (50 µM) + 
NADPH (500 µM) + reductase (33 mU/mL) (S = 0.58 ± 0.10); lanes 2-6, 60 (50 µM) + NADPH (500 µM) 
+ reductase (33 mU/mL) + methanol (500 mM, lane 2) (S = 0.36 ± 0.06); ethanol (500 mM, lane 3) (S = 
0.36 ± 0.06); tert-butyl alcohol (500 mM, lane 4) (S = 0.38 ± 0.05); DMSO (500 mM, lane 5) (S = 0.35 ± 
0.06); mannitol (500 mM, lane 6) (S = 0.37 ± 0.09);. The value S represents the mean number of strand 
breaks per plasmid molecule and is calculated using the equation S = –ln fI, where fI is the fraction of 
plasmid present as form I. 
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Figure 4.8. Comparison of DNA cleavage by reductively activated 33 (blue), 55 (red) or 60 (green) under 
anaerobic conditions and DNA cleavage is inhibited by radical scavengers. Supercoiled plasmid DNA (33 
µg/mL, pGL-2 Basic) was incubated with drug (50µM), NADPH (500 µM), cytochrome P450 reductase 
(33 mU/mL), catalase (100 µg/mL), superoxide dismutase (10 µg/mL), sodium phosphate buffer (50 mM, 
pH 7.0), acetonitrile (0.5-2.5% v/v), and desferal (1 mM) under anaerobic conditions at room temperature 
for 4 h, followed by agarose gel electrophoretic analysis. Lane 1, drug (50 µM) + NADPH (500 µM) + 
reductase (33 mU/mL); lanes 2-6, drug (50 µM) + NADPH (500 µM) + reductase (33 mU/mL) + methanol 
(500 mM, lane 2); ethanol (500 mM, lane 3); tert-butyl alcohol (500 mM, lane 4); DMSO (500 mM, lane 
5); mannitol (500 mM, lane 6); The values, S, derived from agarose gel data and represent the mean 
number of strand breaks per plasmid molecule and were calculated using the equation S = –ln fI, where fI is 
the fraction of plasmid present as form I.  Background cleavage in the untreated plasmid was subtracted to 
allow direct comparison of DNA cleavage yields between different experiments. 
4.7 Examining the chemical mechanism of bioreductive metabolism of 55 and 60 
Metabolite identification showed that the reductive activation of drugs under 
anaerobic conditions produced 1-N–oxide. In this way, the metabolism mirrors TPZ.20 
Cytotoxicity assay results of TPZ and 55 show comparable anti-cancer activity. Hence, it 
can be suggested that TPZ and 55 would follow the same mechanism of DNA damage 
which forms the oxidizing radical under reductively activated conditions in hypoxia. To 
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test the DNA damaging mechanism, we designed comparative metabolic experiments 
with 55 and the isotopically labeled analog of 55, 60. 
4.8 Metabolic studies of 55 and 60 with organic substrate 
Metabolic studies were carried out to test the metabolism of 60 and 55 by 
enzymatic reducing system in the presence of an organic substrate. To test the 
metabolism of 60, NADPH:cytochrome P450 reductase and NADPH was used as the 
enzyme system and CH3OH was added as the organic substrate. The reaction was carried 
out under anaerobic conditions in aqueous sodium phosphate buffer at pH 7.4. Upon 
metabolism the reaction mixture was subjected to be analyzed by LC/MS for the 
metabolites of 60. Anaerobic metabolism of 60 produced 63 as the major metabolite with 
64 and 65 as minor metabolites. In a metabolic analysis carried out using 55 with CD3OD 
in deuterated water under anaerobic conditions using sodium phosphate buffer at pD 6.6 
produced major metabolite 59 and minor metabolites 66 and 67 (Scheme 4.5). 
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Scheme 4.5 Enzymatic metabolism of 60 and 55 with organic substrate in anoxia 
The complete LC/MS analysis for the metabolism of 60 shows retained deuterium 
in metabolites 63, 64 and 65 (Figure 4.9 panels A, C, D and E). Hence benzotriazine 
radical 58 is unlikely to be formed in the bio-reductive metabolism of 60 (Scheme 4.4). 
Moreover, in the LC/MS analysis of metabolites 59, 66 and 67, derived from metabolism 
of 55 shows no exchange of deuterium into metabolites (Figure 4.9 panels F, H, I and J). 
Similar to the metabolism of 60, compound 55 may not form the benzotriazine radical 58 
over the anaerobic bio-reduction process (Scheme 4.4).  
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Figure 4.9. LC/MS analysis of anaerobic metabolism of 55 and 60 (0.5 mM) by cytochrome p450 
reductase (0.4 U/mL) and NADPH (0.5 mM).  The enzymatic reduction of 55/60 was carried out as 
described in the experimental section.  The reaction was dried and products dissolved in methanol.  The 
mixture was eluted with a gradient of 99% A (water containing 0.1% acetic acid) and 1% B (acetonitrile 
containing 0.1% acetic acid) followed by linear increase to 90% B over 30 min.  The elution was continued 
at 90% B for 3 min and then B was decreased to 1% over next 8 min.  A flow rate of 0.35 mL/min was used 
and the metabolites were detected at 254 nm.  Mass spectra were obtained using electrospray ionization in 
the positive ion mode.  Panel A: HPLC of the anaerobic reaction mixture of 60 monitoring absorbance at 
254 nm.  Panel B:  LC/MS of 60; eluting at 9.2 min.  Panel C: LC/MS of metabolites of 60; product eluting 
at 12.45 min.  Panel D:  LC/MS of metabolites of 60; product eluting at 14.30 min.  Panel E:  LC/MS of 
metabolites of 60; product eluting at 15.00 min.  Panel F: HPLC of the anaerobic reaction mixture of 55 
monitoring absorbance at 254 nm. Panel G:  LC/MS of 55 eluting at 9.25 min.  Panel H: LC/MS of 
metabolites of 55; product eluting at 12.54 min.  Panel I:  LC/MS of metabolites of 55; product eluting at 
14.36 min.  Panel J:  LC/MS of metabolites of 55; product eluting at 15.12 min.   
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LC/MS analysis of authentic 60, 63, 55, and 59, using the same LC/MS method, 
used to analyze anaerobic reaction mixtures of 60 and 55 metabolism shows comparable 
retention times and mass values with that of LC/MS analysis of 60 and 55 shown in 
figure 4.11. 
 
 
 
 
 
 
 
 
 
Figure 4.10. LC/MS analysis of authentic 60, 63, 55 and 59. The products dissolved in methanol. The 
mixture was eluted with a gradient of 99% A (water containing 0.1% acetic acid) and 1% B (acetonitrile 
containing 0.1% acetic acid) followed by linear increase to 90% B over 30 min.  The elution was continued 
at 90% B for 3 min and then B was decreased to 1% over next 8 min.  A flow rate of 0.35 mL/min was used 
and the metabolites were detected at 254 nm.  Mass spectra were obtained using electrospray ionization in 
the positive ion mode.  Panel A: HPLC of 60 monitoring absorbance at 254 nm.  Panel B:  LC/MS of 60 
eluting at 8.56 min.  Panel C: HPLC of 63 monitoring absorbance at 254 nm Panel D:  LC/MS of 63 eluting 
at 15.04 min. Panel E:  HPLC of 55 monitoring absorbance at 254 nm.  Panel F: LC/MS of 55 eluting at 
9.03 min.  Panel G: HPLC of 59 monitoring absorbance at 254 nm.   Panel H: LC/MS of 59 eluting at 14.20 
min.   
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4.9 Deuterium incorporation into 55  
The dehydration mechanism is further tested using 55 and 60 (Scheme 4.4). In the 
initial one electron reduction step the di-oxide 55 or 60 will convert to a radical anion and 
upon protonation, drug radicals 57 and 62 may persist under low oxygen levels. In order 
to follow the dehydration mechanism, removal of water molecule from 57 and 62 should 
form radical cation 58 and 58 can abstract hydrogen from an organic substrate (Scheme 
4.4). If the dehydration mechanism is plausible, the hydrogen of organic substrate may be 
abstracted into the major metabolite. HRMS analysis of major metabolite is able to show 
isotopic content which shows any hydrogen abstraction event (Scheme 4.4). To test the 
dehydration mechanism, 55 was activated in the presence of CD3OD, in D2O-sodium 
phosphate buffer medium at pD 6.6. The major metabolite 1-N oxide was separated and 
HRMS data suggests molecular formula C7H5N3O for the molecular ion peak (M) with 
m/z of 147.1. Formation of 63, resulted by dehydration mechanism might have produced 
a molecular ion peak having m/z of 148.1, which is the M+1 ion in the current assay. The 
intensity of M+1 ion is 2% higher than that of a control experiment, carried out using 55 
in the presence of CH3OH in aqueous sodium phosphate buffer at pH 7.4. The 2% 
difference of m/z of M+1, between 55 in CD3OD reaction and 55 in CH3OH control may 
have caused due to the presence of naturally abundant isotopes such as 13C, 15N and 2H 
or may be occurrence of dehydration mechanism as a minor reaction (Figure 4.11).  
116 
 
 
 
 
 
 
 
 
 
Figure 4.11. HRMS of the major metabolite 1-N-oxide 59 arising from metabolism of 55 under reductively 
activated conditions in hypoxia. Briefly 55 (10 mM) was incubated with NADPH (500mM) and 
NADPH:cytochrome P450 reductase (0.5 U/mL) in argon purged bag with either A) sodium phosphate 
buffer (30 mM) at pD 6.6 in D2O and CD3OD (2 mM) were added and incubated over 4 hours. B) sodium 
phosphate buffer (30 mM) at pH 7.4 in H2O and CH3OH ( 2M) were added and incubated over 4 hours. 
Upon completion reactions A and B were extracted to EtOAc and dried in vacuum. Thin layer 
chromatography was used to separate the major 1-N-oxide metabolite in both A and B. Then corresponding 
area related to the Rf value for 1-N-oxide was scratched using a metal blade to collect silica. The organic 
material was extracted to EtOAc from silica and dried in vacuum. The dry organic extract was dissolved in 
CH3CN and directed for HRMS analysis.   
4.10 Isotope washout from drug 60 
Metabolism of 60 was carried out under anaerobic reducing conditions in the 
presence of CH3OH in sodium phosphate buffer at pH 7.4 to study the isotopic content of 
the major metabolite using HRMS. Under dehydration mechanism, deuterium of 60 is 
removed as water and the major metabolite 59 may form via benzotriazinyl radical 58 
(Scheme 4.4). HRMS analysis of molecular ion (M) of the major metabolite shows 
C7H4DN3O as the molecular formula with m/z of 148.1. Due to dehydration mechanism, 
if 59 had formed, m/z of the molecular ion should be 147.1 m/z. When the peak intensity 
of M-1 ion, formed from the reaction 60 with CH3OH is compared with the control, 60 
with CD3OD in D2O-sodium phosphate buffer medium at pD 6.6, shows only 3% 
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increase in the former reaction, 60 with CH3OH. This 3% increase might have occurred 
due to dehydration mechanism, which had occurred as a minor reaction path (Figure 
4.12).  
 
 
 
 
 
Figure 4.12. HRMS of the major metabolite 1-N-oxide 63 arising from metabolism of 60 under reductively 
activated conditions in hypoxia. Briefly 60 (10.mM) was incubated with NADPH (500mM) and 
NADPH:cytochrome P450 reductase (0.5 U/mL) in argon purged bag with either A) sodium phosphate 
buffer (30mM) at pH 7.4 in H2O and CH3OH (2 mM) were added and incubated over 4 hours. B) Sodium 
phosphate buffer (30 mM) at pD 6.6 in D2O and CD3OD (2 mM) were added and incubated over 4 hours. 
Upon completion reactions A and B were extracted to EtOAc and dried in vacuum. Thin layer 
chromatography was used to separate the 1-N-oxide in A and B. Then corresponding area related to the Rf 
value for 1-N-oxide was scratched using a metal blade to collect silica. The organic material was extracted 
to EtOAc and dried in vacuum. The dry organic extract was dissolved in CH3CN and directed for HRMS 
analysis. 
 
4.11 Isotope replacement analysis and dehydration mechanism 
The results of metabolic experiments of 55, with CD3OD and 60 in the presence 
of CH3OH suggest that the dehydration mechanism may occur as a minor path, 
responsible for enzyme mediated activation of 1,2,4-benzotraizine-1,4-dioxides under 
hypoxia. Alternatively, hemolysis of N-O bond, which is evident by radical scavenging 
studies, suggests that hydroxyl radical might be the oxidizing radical formed in the 
metabolism of 55 and 60. The homolytic fragmentation over the bio-reductive 
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metabolism of 55 and 60 is possible to occur as the major metabolic path under hypoxic 
bio-reductive conditions.  
4.12 Conclusion 
The work related to this chapter describes the use of 1,2,4-benzotriazine-1,4-
dioxide 55 as a mechanistic handle to analyze dehydration mechanism. The dehydration 
mechanism is proposed to explain the chemical structure of the oxidizing radical, 
released by these N oxide drugs in hypoxia under reductive activation.10, 12, 26 The drug 
1,2,4-benzotriazine-1,4-dioxide may have formed benzotriazinyl radical as a minor 
oxidizing radical via dehydration mechanism.10 In our study we showed that drugs 55 and 
60 produce DNA cleavage, comparable to the DNA damage caused by 33. In addition, 
the radical scavenging experiments with 33, 55 and 60 showed reduced DNA damage and 
diminished DNA damage suggest the involvement of hydroxyl radical as the major DNA 
damaging process.4a, 14c  
The results of the experiments, carried out to test deuterium incorporation to 55 in 
the presence of CD3OD and deuterium release from 60, in the presence of CH3OH were 
not consistent with the dehydration mechanism as the major mechanism in the enzymatic 
metabolism of 1,2,4-benzotriazine-1,4-dioxide.  
Finally, based on various experiment results related to mechanistic studies on N-
di-oxides, it can be concluded that the one electron reduction of 1,2,4-benzotriazine-1,4-
dioxide produces hydroxyl radical as the oxidizing species which might be the major 
source that carries out DNA cleavage.  
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4.13 Experimental 
4.12.1 Materials.  Materials were of the highest purity available and were obtained from 
following sources:  cytochrome P450 reductase, NADPH, sodium phosphate, mannitol, 
DMSO desferal, , catalase, and superoxide dismutase (SOD) from Sigma Chemical Co. 
(St. Louis, MO); agarose from Seakem; HPLC grade solvents (acetonitrile, methanol, 
ethanol, tert-butyl alcohol, ethyl acetate, hexane, and acetic acid) from Fischer 
(Pittsburgh, PA); ethidium bromide from Roche Molecular Biochemicals (Indianapolis, 
IN).  Standard protocol was used to prepare plasmid DNA pGL2BASIC.27 Published 
methods in literature were followed to prepare TPZ 1 and other N-oxides.20a, 28  
4.12.2  Synthesis of 1,2,4-benzotriazine-1,4-bioxide 55 
Argon was purged into dry DMF for 5 min inside an argon filled glove bag. Then 
TPZ (115mg, 0.644 mmol) was dissolved in (2 mL) DMF. To another degassed DMF 
sample (2 mL) tert-butyl nitrite (0.25 ml, 2.05 mmol) was added and heated to 650C 
inside the glove bag. To this solution, TPZ was added and heated for 10 min at 650C with 
stirring. Upon completion reaction time the reaction mixture was cooled to room 
temperature and DMF was removed by vacuum. Then column chromatography (1:1 
EtOAc/hexane) was performed to obtain (40 mg, 34 %). Deuterated DMF was used in the 
preparation of 3 position deuterated 1,2,4-benzotriazine-1,4-dioxide. Rf of is 0.50 (100% 
EtOAc): 1H NMR (Acetone, 500 MHz,): δ 9.04 (s, 1H), 8.42 (dd, 2H), 8.15 (m, 1H), 8.03 
(m, 1H). 13C-NMR (Acetone, 125.8 MHz,): δ 142.73, 141.01, 136.50, 136.01, 133.54, 
122.20, 120.19; HRMS (ES+, [M+H]) m/z calcd C7H6N3O2 calculated mass 164.0460; 
actual mass 164.0453. 
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4.12.3  Synthesis of 3 position deuterated 1,2,4-benzotriazine-1,4-dioxide 60 
The procedure used to synthesize 55 was followed to prepare 60. In synthesis, 
deuterated DMF was used instead of DMF.  
1H NMR (Acetone, 500 MHz,): δ 8.42 (dd, 2H), 8.15 (m, 1H), 8.03 (m, 1H). 13C-NMR 
(Acetone, 125.8 MHz,): δ 142.47 (t, J = 32.7 Hz), 141.02, 136.52, 136.02, 133.54, 
122.20, 120.18; HRMS (ES+, [M+H]) m/z calcd C7H5DN3O2 calculated mass 165.0523; 
actual mass 165.0515. 
4.12.4  Synthesis of 1,2,4-benzotriazine-1-oxide 59 
Anhydrous DMF was bubbled with argon for 5 min inside a argon filled glove 
bag. Then 35 (365mg, 2.2 mmol) was dissolved in (3 mL) DMF. To another DMF sample 
(3 mL) tert-butyl nitrite (1.07 ml, 8.8 mmol) was added and heated to 650C inside the 
glove bag. To this solution TPZ was added and heated for 10 min at 650C with stirring. 
Upon completion reaction time the reaction mixture was cooled to room temperature and 
DMF was removed by vacuum. Then column chromatography (1:1 EtOAc/hexane) was 
performed to obtain (77 mg, 34 %). Rf = 0.50 (100% EtOAc)  
1H NMR (Acetone, 300 MHz): δ ppm 9.05 (s, 1H), δ 8.42 (d, J = 8.5 Hz, 1H), δ 8.11 (m, 
2H), δ 7.91 (m, 1H) 13C NMR (Acetone, 75.5 MHz): δ 155.02, 148.32, 136.66, 131.99, 
130.05, 120.63; HRMS (ES+, [M+H]) m/z calcd C7H6N3O calculated mass 148.0511; 
actual mass 148.0517. 
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4.12.5  Synthesis of 1,2,4-benzotriazine-3-deuterium-1-oxide 63 
The synthetic method used to prepare 59 was exactly followed to synthesized 63 
and deuterated DMF was used instead of DMF. 1H NMR (Acetone, 300 MHz): δ ppm  
8.40 (d, J = 8.5 Hz, 1H), 8.08 (m, 2H), 7.88 (m, 1H) 13C NMR (Acetone, 75.5 MHz): δ 
154.72 (t, J = 32.7 Hz), 148.34, 136.66, 131.99, 130.06, 120.64; HRMS (ES+, [M+H]) 
m/z calcd C7H5DN3O calculated mass 149.0574; actual mass 149.0579. 
 
4.12.6  DNA damage assays 
In normal anaerobic DNA cleaving assay, the drug TPZ, 55 or 61 (5-25 µM) was 
incubated with supercoiled plasmid DNA (33 µg/mL, pGL-2 Basic), NADPH (500 µM), 
cytochrome P450 reductase (33 mU/mL), catalase (100 µg/mL), superoxide dismutase 
(10 µg/mL), sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (0.5-2.5% v/v), and 
desferal (1 mM) under anaerobic conditions at 25 ˚C for 4 h. Three freeze-pump-thaw 
cycles were performed on all solutions except enzymes, NADPH, and DNA. To prepare 
reaction mixtures deoxygenated water was used in an argon-filled glove bag and 
cytochrome P450 reductase was added as the last reagent to start the reaction. Then the 
reaction containers were kept in the argon purged glove bag upon wrapped in aluminum 
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foil to prevent exposure to light. The reactions were quenched by addition of 5 µL of 
50% glycerol loading buffer and were loaded onto a 0.9% agarose gel and 
electrophoresed for approximately 2.0 h at 85 V in 1x TAE buffer. Upon completion of 
electrophoretic separation, the gels were removed and soaked in an aqueous ethidium 
bromide (0.3µg/mL) solution for staining for 4 h. To visualize DNA UV-
transillumination was performed on gels and DNA band quantification was performed 
using quantity one imaging system.  The values reported are not corrected for differential 
staining of form I and form II DNA by ethidium bromide. 
The radical scavenging DNA damage assays were performed following the above typical 
procedure. The radical scavenging reagents methanol, ethanol, tert-butyl alcohol, DMSO, 
or mannitol (500 mM) were added inaddition to the other reagents prior to the addition of  
cytochrome P450 reductase. All aerobic reactions were carried out using non de 
oxygenated soluitons under normal atmosphericconditions.  
4.12.7  Metabolic studies related to drugs 
In a typical metabolic assay, all solutions except cytochrome P450 reductase (330 
mU/mL), catalase (100 µg/mL) were degassed by three cycles of freeze-pump-thaw 
cycles. The N di-oxide (µM) was mixed with desferal (1 mM) in sodium phosphate buffer 
(pH 7, 50 mM), NADPH (500 µM), catalase (100 µg/mL), and superoxide dismutase (10 
µg/mL) followed by the addition of cytochrome P450 reductase (330 mU/mL). Upon 4 hr 
incubation under argon at 25 ˚C, the organic was extracted to EtOAc (0.5 mL) twice and 
dried using roto vap. Then the dry reaction mixture was dissolved in 0.5 mL MeOH and 
was analyzed by LC employing a C18 reverse phase Rainin Microsorb-MV column (5 
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µm particle size, 100 Å pore size, 25 cm length, 4.6 mm i.d.) eluted with gradient starting 
at 50% A (0.5% acetic acid in water) and 50% B (acetonitrile) followed by linear increase 
to 80% B from 0 min to 40 min.  A flow rate of 0.6 mL/min was used and the products 
were monitored by their UV-absorbance at 254 nm. LC/ESI-MS experiments were 
carried out on a Finnigan TSQ 7000 triple quadrupole instrument interfaced to a 
ThermoSeparations liquid chromatograph (TSP4000).  Positive ion electrospray was used 
as the means of ionization.  The heated inlet capillary temperature was 250 °C and 
electrospray needle voltage was 4.5 kV.  Nitrogen sheath gas was supplied at 80 psi and 
the LC/ESI-MS analysis was done in the positive ion mode. 
4.12.8 HRMS studies related to drugs 
In a typical metabolic assay, all solutions except cytochrome P450 reductase (330 
mU/mL), catalase (100 µg/mL) were degassed by three cycles of freeze-pump-thaw 
cycles. The N di-oxide (µM) was mixed with desferal (1 mM) in sodium phosphate 
buffer (pH 7, 50 mM) and NADPH (500 µM) followed by the addition of cytochrome 
P450 reductase (330 mU/mL). Upon 4 hr incubation under argon at 25 ˚C, the organic 
was extracted to EtOAc (0.5 mL) twice and dried using roto vap. Then the dry reaction 
mixture was dissolved in 0.5 mL CH3CN and used to spot on TLC plates. The preparative 
TLC was run using (1:1 EtOAc/hexane) as the solvent system. The major metabolite 
mono N oxide was co-spotted when preparation TLC was run. Upon completion the TLC 
plates were dried in air and the area correspond to 1-N-oxide co-migration was scratched 
using a metal blade. The dry silica was re-dissolved in EtOAc and EtOAc was removed 
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to a glass vial. The EtOAc was dried under roto-vap, protected from light and kept in the 
freezer. The dry samples were sent for HRMS analysis.  
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1H NMR of 55 (Acetone, 500 MHz) 
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13C NMR of 55 (Acetone, 125.77 MHz) 
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1H NMR of 60 (Acetone, 500 MHz) 
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13C NMR of 60 (Acetone, 125.77 MHz) 
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1H NMR of 59 (Acetone, 300 MHz) 
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13C NMR of 59 (Acetone, 75 MHz) 
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1H NMR of 63 (Acetone, 500 MHz) 
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13C NMR of 63 (Acetone, 125.77 MHz) 
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Chapter 5  
Synthesis of bioreductivly activated nitroaromatic triggers  
5.1. Qualitative and quantitative determination of hypoxia 
 
 Chapters 1, 2 and 3 described the importance of hypoxia or low oxygen 
concentration to tumor physiology and tumor therapy. Detection and quantification of 
oxygen levels is immerging as an important tool in the treatment of tumors.1 Various 
methods of characterization for tumor hypoxia have been introduced to the research 
community.2 As discussed in previous chapters, there is a demand for suitable fluorescent 
probes to detect hypoxia.3 A complete description of small molecule fluorescent probe, 
which can detect hypoxia, was included in chapters 2 and 3. In a similar approach, a 
compound which can undergo hypoxia selective enzymatic bioreduction and maintain 
oxygen sensitive reduction may be coupled to a fluorophore, to construct fluorescent 
probes to detect hypoxia.4 Nitroaromatic compounds such as para nitrobenzyl, 2-
nitroimidazole and 5-nitrothienyl groups and tirapazamine might be used as a 
bioreductive aromatic compound which can undergo oxygen-sensitive reduction and 
release the fluorescent molecule (Scheme 5.1). 
 
 
 
 
 
 
 
 
Scheme 5.1. Bioreducible moieties can be used as oxygen sensors 
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5.2 Goal: Constructing suitable nitroaromatic fluorescent probe for hypoxia 
Current research on bio-reductive pro-drugs  suggests that oxygen sensitive bio-
reducible species such as nitro-benzyl, 2-nitroimidazole and 5-nitrothienyl groups, when 
appended to cytotoxic agents to mask the drug activity, show encouraging selective drug 
delivery toward low oxygenated tumors. In order to test the performance of nitro-phenyl 
group as an oxygen sensor, Borche and coworkers attached phosphoramidite toxin to 
produce series of prodrugs (Scheme 5.2).5 Following the same design strategy, 
fluorophores can be attached to nitroaromatic groups using suitable coupling reactions. 
 
 
 
 
Scheme 5.2. Nitrophenyl benzyl phosphoramadite prodrugs 
The in vitro cytotoxicity studies with 26 suggest that nitrophenyl may be a 
suitable bioreducible moiety which can be reduced enzymatically in hypoxia. The 
reduction process produces electron rich hydroxylamine or amine compounds which can 
ultimately release the active compound and imine methide upon 1-6 elimination (Scheme 
5.3).  
 
 
 
Scheme 5.3. 1,6-elimination of active drug species 
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Such a prodrug, with a flourophore, was made using nitrophenyl benzyl bromide 
68, over a nucleophilic displacement reaction with 7-hydroxyl-4-methyl coumarine 69, a 
known fluorophore which possess a better stokes shift and quantum yield, to produce 
nitrophenyl-coumarin compound 70 (Scheme 5.3).6 
 
 
 
 
 
Scheme 5.4. Synthesis of 70 
 
Bioreductive in vitro assays were carried out using 70, with NADPH:cytochrome 
p450 reductase;NADPH and xanthine:xanthine oxidase reducing systems. The poor 
release of 69 is comparable to low amount of release of thiopurine, which was attached to 
nitrobenzyl in the pro-drug form.7 While concluding that nitrophenyl group is not 
compatible for enzymatic reducing systems NADPH:cytochrome p450 
reductase;NADPH and xanthine:xanthine oxidase, however we set out to construct other 
nitroaromatic bioreducible groups 5-nitrothienyl and 2-nitroimidazole. 
5.3 Synthesis of 5-nitrothienyl moiety, 2-(5-Nitrothien-2-yl) propan-2-ol (73)  
Nitrothiephenes are bioreducible nitroaromatic group, which can be reduced by 
cellular reductases under low oxygen levels.8 In addition, methyl groups on the benzylic 
carbon facilitates effective drug release from the probe.9 Hence, Nitrothienyl 2-(5-
Nitrothien-2-yl) propan-2-ol 73 was prepared as a nitroaromatic trigger candidate. Methyl 
magnesium bromide was added to 2-acetylthiophene 71, in ethyl ether to afford 
thiophene alcohol 72. Compound 72 was separated by column chromatography. Nitration 
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on the 5 carbon of 72 was done using acetic anhydride: Nitric acid nitration mixture. To a 
cold solution of 72 in acetic anhydride, fuming nitric acid was added while mixing at -
700C.10 Upon neutralizing, using sodium bicarbonate, the product 2-(5-nitrothien-2-yl) 
propan-2-ol (73) was separated and purified using column chromatography (Scheme 5.5). 
 
 
 
Scheme 5.5. Synthesis of 2-(5-nitrothien-2-yl) propan-2-ol 73  
5.4 Synthesis of 1-methyl-2-nitro-5-hydroxymethyl imidazole 79 
The compound 2-nitro-1-methyl imidazole group has been used as a component 
of bioreductive prodrugs.2a, 4a, 11 The amino compound 1-methyl-2-amino-imidazole may 
be used as the starting compound to reach the desired nitro imidazole group. In the 
synthesis, published by Bellani and Lancini was modified in the preparation of 1-methyl-
2-amino-5-carbethoxyimidazole 76.12 Briefly, Ethyl formate was added to ethyl sarcocine 
ester (74) powder and the mixture was cooled below 00C. Then NaH was added gradually 
and stirred for 14 hrs. Then, trituration using hexane produced a thick liquid and was 
separated from hexane. The residue was mixed with ethanol and HCl, followed by 
heating at 1000C with vigorous stirring for 1 hr. Then the reaction was cooled and added 
with cyanamide, 10% acetic acid and sodium acetate and heated at 900C for 90 min. Then 
the reaction was cooled and the pH adjusted to 1 using HCl. The solvent was removed by 
rotary evaporation below 450C until the volume had reduced to one fifth of the initial 
volume. Then the pH was raised to 8-9 using KHCO3. Ethyl acetate was used to separate 
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organic layer and the extract was dried with MgSO4. Compound 76 was isolated by 
column chromatography (Scheme 5.5).  
 
 
 
Scheme 5.6. Synthesis of 76 from sarcocine ethyl ester 74 
The nitration of 76 afforded the nitro imidazole compound 1-methyl-2-nitro-5-
carbethoxyimidazole 77. In the synthesis, the compound 79 was added to acetic acid and 
the acetic acid/79 mixture was added to a sodium nitrite solution, which is at 00C, drop 
wise while stirring. Overnight stirring at room temperature was followed by extraction of 
the organic material into methylene chloride. The methylene chloride layer was dried 
over MgSO4. Compound 77 was separated using column chromatography.13 The ester 
bond of 77 was hydrolyzed using 1N NaOH to obtain 78. The carboxylic group of 78 was 
reduced using NaBH3 and isoformyl chloroformate.14 The resulting solution was 
extracted with THF and the dry organic material was column chromatographed to obtain 
79 (Scheme 5.7).  
 
 
 
 
Scheme 5.7. Synthesis of 1-methyl-2-nitro-5-hydroxymethyl imidazole 79 
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5.5 Synthesis of 80 and 81 
Prodrugs 80 and 81 may be made employing Mitsonobu coupling reactions. The 
nitroaromatics 73 and 79 were reacted with the coumarin fluorophore 69 under 
Mitsonobu conditions. The attempts to make compounds 80 and 81 were not successful 
(Scheme 5.8).  
 
 
 
 
Scheme 5.8. Fluorescent probes 83 and 84. 
5.7 Synthesis of 3-acetylquinoline-1,2,4-benzotraizine 1,4-dioxide 84 
In an separate effort to prepare a probe for hypoxia was done by coupling 3-
amino-1,2,4-benzotraizine 1,4-dioxide (TPZ), 33 with 6-aminoquinoline 43, a known 
fluorophore. TPZ was reacted with triphosgene 82 to produce intermediate 83 and then, 
43 was added in situ to obtain 84 (Scheme 5.9).15  
 
 
 
Scheme 5.9. Synthesis of 84 using triphosgene 82, 33 and 43  
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5.8 Experimental 
5.7.1 Synthesis of paranitrophenyl-4-methyl-coumarin ether (70)  
To a slurry of NaH (148 mg, 6.16 mmol) in dry DMF (10 mL), at 00C was added 
with 69 (542.6 mg, 3.08 mmol), in dry DMF. Then 68 (1000 mg, 4.6 mmol) was added to 
the mixture and was stirred at 00C for 12 h. Upon disappearance of 69 on TLC, the 
mixture was extracted to EtOAc, dried with brine and column chromatographed to obtain 
the ether 70 (214 mg, Rf value = 0.5 in 50% hexane in EtOAc). 1H NMR (CDCl3, 500 
MHz): δ ppm 8.27 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.5 Hz, 2H), 7.53 (d, J = 8.5 Hz, 1H), 
6.94 (d, J = 8.5 Hz, 1H), 6.87 (s, 1H), 6.16 (s, 1H), 5.24 (s, 1H), 2.40 (s, 1H).13C NMR 
(CDCl3, 125.5 MHz): δ 160.9, 155.2, 152.3, 143.1, 127.7, 125.8, 123.9, 114.3, 112.7, 
112.5, 101.9, 69.0, 18.7. LRMS (ESI, [M+H]+) m/z calcd for C17H14N1O5 312.09 
calculated, found 311.95.  
5.7.2 Synthesis of 2-thien-2-yl-propan-2-ol (72)  
Compound 71, 2-acetylthiophene (18 mL, 143 mmol) was dissolved in 300 mL 
Et2O at 00C and stirred. Then nitrogen was purged. Methyl magnesium bromide (65 mL 
from 3M in Et2O solution) was added via a syringe. Then the reaction mixture was stirred 
at room temperature for 4 hr. The reaction mixture was extracted into CH2Cl2 and dried 
with brine and MgSO4. Column chromatography afforded 72 (4.39 g, Rfvalue = 0. 4 in 
100% CH2Cl2). 1H NMR (CDCl3, 300 MHz): δ ppm 7.17 (d, J = 4.5 Hz, 1H), 6.93 (m, 
2H), 1.66 (m, 6H).13C NMR (CDCl3, 75.5 MHz): δ 154.7, 126.9, 124.1, 122.3, 71.6, 32.5. 
HRMS (ESI, [M+H]+) m/z calcd for C7H10OS 142.0445 calculated, found 142.0452.  
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5.7.3 Synthesis of 2-Thien-2-yl-Propan-2-ol (73) 
The thienyl alcohol 2-thien-2-yl-Propan-2-ol 72 (2 g, 10.6 mmol) was dissolved 
in 30 mL acetic acid and cooled to -700C using MeOH dry ice slurry. While stirring, 
fuming HNO3 (0.7 mL, 11.6 mmol) was gradually added with vigourous stirring and 
reaction was run for 2 hr. Then another hour stirring was done at -400C. Temperature was 
raised to 00C and stirred for another 1 hr. Then water/ice 200 g was added and EtOAc 
(100 mL) was used to extract organic material. The EtOAc layer was dried using Na2SO4. 
Column chromatography performed to separate 73 (310 mg, Rf value = 0. 2 with 20% 
EtOAc in hexane) 1H NMR (CDCl3, 300 MHz): δ ppm 7.78 (d, J = 4.5 Hz, 1H), 6.86 (d, J 
= 4.5 Hz, 1H), 1.66 (m, 6H). 13C NMR (CDCl3, 75.5 MHz): δ 163.6, 128.8, 121.2, 71.8, 
31.9. HRMS (ESI, [M+H]+) m/z calcd for C7H9O3NS 187.0303 calculated, found 
187.0299. 
5.7.4 Synthesis of 1-methyl-2-amino-5-carbethoxyimidazole (76)  
Ethyl formate (62.5 mL) was added to sarcosine methylester hydrochloride 74 (10 
g, 71 mmol) in a 500 mL r.b. and chilled at 00C. Sodium hydride (60% oil suspension, 
6.58 g, 0.1645 mmol) was added slowly over 2 h and stirred for 14 h to produce 75.12a 
Then, trituration was done twice using 50 ml of hexane to obtain light brown slurry. The 
brown slurry was added to a new 500 mL r.b. and added with 50 mL EtOH and 8 mL of 
conc. HCl. The mixture was stirred at 900C for 1 hr. Then the mixture was cooled to 
room temperature and filtered. To the filterate, 10 mL of 10% aquoes HOAc, sodium 
acetate (10.73g, 0.13 mmol) and CH3CN (5.5 g, 0.13 mmol) were added and stirred at for 
90 min. The pH was raised to 8-9 using KHCO3 and the organic material was extracted to 
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EtOAc. Ethyl acetate layer was dried using brine and concentrated. The dry organic 
mixture was column chromatographed to obtain 76 (1 g, Rf value = 0. 31 with 2% MeOH 
in EtOAc in hexane) 1H NMR (DMSO, 500 MHz): δ ppm 7.26 (s, 1H), 6.15 (s, 2H), 4.14 
(q, J= 7.0 Hz, 2H), 3.50 (s, 3H), 1.210 (t, J= 7.0 Hz, 3H). 13C NMR (DMSO, 125.5 
MHz): δ 159.0, 154.3, 136.1, 116.86, 58.9, 30.2, 14.4. HRMS (ESI, [M+H]+) m/z calcd 
for C7H12O2N3 170.0930 calculated, found 170.0929. 
5.7.5 Synthesis of 1-methyl-2-nitro-5-carbethoxyimidazole (77)  
Water (20 ml) was added with NaNO2 (3g) and the solution was cooled below -
50C. Then, 1.5 g of 76 in acetic acid was added drop wise to sodium nitrite solution while 
maintaining the temperature below 00C. Upon completion of the reaction, ethyl acetate 
was used to extract organic products. The EtOAc layer was dried using MgSO4. 
Compound 77 was separated by silica gel chromatography (0.6 g, Rf value = 0. 5 in 100% 
CH2Cl2). 1H NMR (CDCl3, 500 MHz): δ ppm 7.73 (s, 1H), 4.38 (m, 5H), 1.40 (s, 3H). 
13C NMR (CDCl3, 125.5 MHz): δ 159.0, 136.5, 134.64, 126.6, 61.8, 35.3, 14.1. HRMS 
(ESI, [M+H]+) m/z calcd for C7H10O4N3 200.0671 calculated, found 200.0669. 
5.7.6 Synthesis of 1-methyl-2-nitro-5-carboxylimidazole (78)  
In 10 mL of 1N NaOH compound 77 (0.6 g, 3.015 mmol) was dissolved and the 
mixture was stirred overnight. The pH was adjusted to 1 using conc. HCl. Then the 
product 78 was extracted to EtOAc and ethyl acetate layer was dried using MgSO4 (0.6 g, 
Rf value = 0.2 in 100% EtOAc). 1H NMR (DMSO, 500 MHz): δ ppm 7.71 (s, 1H), 7.56 
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(s, acidic H), 4.17 (s, 3H). 13C NMR (DMSO, 125.5 MHz): δ 160.71, 147.8, 134.1, 127.3, 
35.4. LRMS (ESI, [M+H]+) m/z calcd for C5H6O4N3 172.03 calculated, found 172.11. 
5.7.7 Synthesis of 1-methyl-2-nitro-5-hydroxymethylimidazole (79)  
A mixture of 78 (70 mg, 0.41 mmol) and triethylamine (0.318 mL, 0.649 mmol) 
in anhydrous THF (1 mL) was cooled in dry acetonitrile bath (-200C). Isobutyl 
chloroformate (100 µL, 7.7 mmol) was added dropwise, over 10 min. Then the reaction 
was stirred over 1 h. Then sodium borohydried (81mg) was added to the reaction mixture. 
Then water was added drop wise over a period of 1h and the temperature was kept below 
00C. The products were extracted to ethyl acetate and dried with brine. Column 
chromatography separated pure 14 (30 mg, Rf value = 0.28 in 100% EtOAc) 1H NMR 
(MeOD, 500 MHz): δ ppm 7.08 (s, 1H), 4.84 (s, 1H), 4.65 (s, 2H), 4.02 (s, 3H). 13C NMR 
(MeOD, 125.5 MHz): δ 147.4, 139.5, 127.6, 54.7, 34.9, HRMS (ESI, [M+H]+) m/z calcd 
for C5H8O3N3 158.0566 calculated, found 158. 0575. 
5.7.7 Synthesis of 3-acetylquinoline-1,2,4-benzotraizine 1,4-dioxide 84 
The compound 33 (0.15 g, 0.85 mmol) was dissolved in dry toluene (2.5 mL) and 
the mixture was stirred and heated to 900C. Then triphosgene 82 (0.086 g, 0.29 mmol) 
was added to the TPZ mixture and the reaction was stirred for 5-10 min. Another batch of 
82 (0.086 g, 0.29 mmol) was added and then the reaction was cooled to obtain crude 83.15 
To the crude 83, 43 (0.15 g, 0.763 mmol) in 2.5 mL DMF was added and stirred at room 
temperature for 10 min. The yellow solid product 84 was separated (0.02 g, Rf value = 
0.1 in 2% MeOH in EtOAc). 1H NMR (DMSO, 500 MHz): δ ppm 10.45 (s, 1H), 10.30 (s, 
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1H), 8.79 (s, 1H), 8.30 (m, 4H), 8.05 (m, 2H),  7.78 (m,2H), 7.51 (d, J = 7.0 Hz, 1H).13C 
NMR (DMSO, 500 MHz): δ 148.7, 148.3, 145.9, 138.0, 136.6, 135.8, 132.5, 129.7, 
128.5, 122.9, 121.9, 121.1, 118.0, 114.0, HRMS (ESI [M+H]+) m/z calcd for C17H13N6O3 
349.1049 calculated, found 349.1057. 
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1H NMR of 70 (CDCl3, 500 MHz) 
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13C NMR of 70 (CDCl3, 125.5 MHz) 
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1H NMR of 72 (CDCl3, 300 MHz) 
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13C NMR of 72 (CDCl3, 75.5 MHz) 
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1H NMR of 73 (CDCl3, 300 MHz) 
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13C NMR of 73 (CDCl3, 75.5 MHz) 
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1H NMR of 76 (DMSO, 500 MHz) 
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13C NMR of 76 (DMSO, 125.5 MHz) 
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1H NMR of 77 (CDCl3, 500 MHz) 
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1H NMR of 78 (DMSO, 500 MHz) 
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1H NMR of 79 (MeOD, 500 MHz) 
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13C NMR of 79 (MeOD, 500 MHz) 
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1H NMR of 84 (MeOD, 500 MHz) 
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13C NMR of 84 (MeOD, 125.7 MHz) 
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